BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237. [PMID: 14657227 DOI: 10.1200/jco.2004.05.113] [Cited by in Crossref: 2092] [Cited by in F6Publishing: 621] [Article Influence: 116.2] [Reference Citation Analysis]
Number Citing Articles
1 Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK. The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient’s status. Int J Colorectal Dis. 2007;22:1301-1310. [PMID: 17486358 DOI: 10.1007/s00384-007-0315-x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
2 Okita A, Takahashi S, Ouchi K, Inoue M, Watanabe M, Endo M, Honda H, Yamada Y, Ishioka C. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget. 2018;9:18698-18711. [PMID: 29721154 DOI: 10.18632/oncotarget.24617] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 20.0] [Reference Citation Analysis]
3 Bredt LC, Rachid AF. Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2014;12:391. [PMID: 25528650 DOI: 10.1186/1477-7819-12-391] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
4 Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999. [PMID: 16538219 DOI: 10.1038/sj.bjc.6603033] [Cited by in Crossref: 593] [Cited by in F6Publishing: 456] [Article Influence: 39.5] [Reference Citation Analysis]
5 Ho MY, Renouf DJ, Cheung WY, Lim HJ, Speers CH, Zhou C, Kennecke HF. Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer. Curr Oncol 2016;23:329-33. [PMID: 27803597 DOI: 10.3747/co.23.3030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
6 Belardinilli F, Capalbo C, Malapelle U, Pisapia P, Raimondo D, Milanetti E, Yasaman M, Liccardi C, Paci P, Sibilio P, Pepe F, Bonfiglio C, Mezi S, Magri V, Coppa A, Nicolussi A, Gradilone A, Petroni M, Di Giulio S, Fabretti F, Infante P, Coni S, Canettieri G, Troncone G, Giannini G. Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Front Oncol 2020;10:560. [PMID: 32457828 DOI: 10.3389/fonc.2020.00560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 2015;76:925-32. [PMID: 26370544 DOI: 10.1007/s00280-015-2850-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
8 Ewara EM, Zaric GS, Welch S, Sarma S. Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer. Curr Oncol 2014;21:e541-50. [PMID: 25089105 DOI: 10.3747/co.21.1837] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ricci V, Granetto C, Falletta A, Paccagnella M, Abbona A, Fea E, Fabozzi T, Lo Nigro C, Merlano MC. Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib. World J Gastrointest Oncol 2020;12:301-10. [PMID: 32206180 DOI: 10.4251/wjgo.v12.i3.301] [Reference Citation Analysis]
10 Tsujimoto H, Tsukioka S, Ono S, Sakamoto E, Sakamoto K, Tsuta K, Nakagawa F, Saito H, Uchida J, Kiniwa M, Fukushima M. Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. Oncol Lett 2010;1:973-80. [PMID: 22870097 DOI: 10.3892/ol.2010.172] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 McAuliffe JC, Qadan M, D'Angelica MI. Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer. J Gastrointest Oncol 2015;6:699-708. [PMID: 26697204 DOI: 10.3978/j.issn.2078-6891.2015.081] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
12 Wrobel P, Ahmed S. Current status of immunotherapy in metastatic colorectal cancer. Int J Colorectal Dis 2019;34:13-25. [PMID: 30465238 DOI: 10.1007/s00384-018-3202-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
13 Tang PA, Moore MJ. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol. 2013;6:459-473. [PMID: 24179482 DOI: 10.1177/1756283x13502637] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
14 Clarke S, Burge M, Cordwell C, Gibbs P, Reece W, Tebbutt N. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. BMC Cancer 2013;13:120. [PMID: 23497305 DOI: 10.1186/1471-2407-13-120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
15 Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, Colucci G, Gerunda GE, Depenni R, Zironi S, Fontana A, Pettorelli E, Luppi G, Conte PF. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer 2011;104:1079-84. [PMID: 21386839 DOI: 10.1038/bjc.2011.43] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
16 Tanoue Y, Tanaka N, Nomura Y. Primary site resection is superior for incurable metastatic colorectal cancer. World J Gastroenterol 2010;16:3561-6. [PMID: 20653065 DOI: 10.3748/wjg.v16.i28.3561] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
17 Mokarram P, Albokashy M, Zarghooni M, Moosavi MA, Sepehri Z, Chen QM, Hudecki A, Sargazi A, Alizadeh J, Moghadam AR, Hashemi M, Movassagh H, Klonisch T, Owji AA, Łos MJ, Ghavami S. New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. Autophagy 2017;13:781-819. [PMID: 28358273 DOI: 10.1080/15548627.2017.1290751] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 18.8] [Reference Citation Analysis]
18 Feliu J, Castañón C, Salud A, Mel JR, Escudero P, Pelegrín A, López-Gómez L, Ruiz M, González E, Juárez F, Lizón J, Castro J, González-Barón M; Oncopaz Cooperative Group, Spain. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer 2005;93:1230-5. [PMID: 16265344 DOI: 10.1038/sj.bjc.6602860] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
19 Yoshidome H, Kimura F, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Mitsuhashi N, Takeuchi D, Iida A, Miyazaki M. Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? J Gastrointest Surg. 2008;12:1391-1398. [PMID: 18491195 DOI: 10.1007/s11605-008-0540-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
20 Sasaki Y, Osada S, Mori R, Imai H, Tanaka Y, Matsuhashi N, Okumura N, Nonaka K, Takahashi T, Yoshida K. Determining timing of hepatectomy for colorectal cancer with distant metastasis according to imaging-based tumor shrinkage ratio. Int J Med Sci 2013;10:1231-41. [PMID: 23935401 DOI: 10.7150/ijms.6244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Hirokawa F, Asakuma M, Komeda K, Shimizu T, Inoue Y, Kagota S, Tomioka A, Uchiyama K. Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer? Surg Today 2019;49:82-9. [DOI: 10.1007/s00595-018-1716-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Ikeguchi M, Yamamoto M, Arai Y, Maeta Y, Ashida K, Katano K, Miki Y, Kimura T. Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer. Oncol Lett 2011;2:319-22. [PMID: 22866084 DOI: 10.3892/ol.2011.254] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
23 Burge ME, Smith D, Topham C, Jackson DP, Anthoney DA, Halstead F, Seymour MT. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer 2006;94:1281-6. [PMID: 16622464 DOI: 10.1038/sj.bjc.6603084] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
24 Páez D, Tobeña M, Fernández-Plana J, Sebio A, Virgili AC, Cirera L, Barnadas A, Riera P, Sullivan I, Salazar J. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Br J Cancer 2019;120:190-5. [PMID: 30585257 DOI: 10.1038/s41416-018-0348-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
25 Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007;11:1112-1119. [PMID: 17623263 DOI: 10.1007/s11605-007-0218-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
26 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Des Devel Ther 2015;9:1653-62. [PMID: 25834402 DOI: 10.2147/DDDT.S80449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Tokumaru Y, Matsuhashi N, Takahashi T, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Yoshida K. Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report. Mol Clin Oncol 2019;10:571-4. [PMID: 31031973 DOI: 10.3892/mco.2019.1836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Saif MW. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol 2009;15:3855-64. [PMID: 19701965 DOI: 10.3748/wjg.15.3855] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
29 Losa F, Barrios P, Salazar R, Torres-melero J, Benavides M, Massuti T, Ramos I, Aranda E. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Oncol 2014;16:128-40. [DOI: 10.1007/s12094-013-1053-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
30 Govaert KM, van Kessel CS, Lolkema M, Ruers TJ, Borel Rinkes IH. Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases? Curr Colorectal Cancer Rep. 2012;8:130-137. [PMID: 22611343 DOI: 10.1007/s11888-012-0122-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
31 Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:57-84. [PMID: 26753006 DOI: 10.1177/1758834015614530] [Cited by in Crossref: 203] [Cited by in F6Publishing: 167] [Article Influence: 40.6] [Reference Citation Analysis]
32 Xu W, Kuang M, Gong Y, Cao C, Chen J, Tang C. Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. Onco Targets Ther 2016;9:4833-42. [PMID: 27536147 DOI: 10.2147/OTT.S104981] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
33 Ishihara S, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Kazama S, Yamaguchi H, Sunami E, Kitayama J, Sugihara K, Watanabe T. Benefit of primary tumor resection in stage IV colorectal cancer with unresectable metastasis: a multicenter retrospective study using a propensity score analysis. Int J Colorectal Dis 2015;30:807-12. [PMID: 25922146 DOI: 10.1007/s00384-015-2228-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
34 Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, Schroeder M, Klein O, Höhler T, Galle PR, Heike M, Moehler M. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 2004;4:38. [PMID: 15265233 DOI: 10.1186/1471-2407-4-38] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
35 Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer 2019;1871:434-54. [PMID: 31034926 DOI: 10.1016/j.bbcan.2019.04.005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 43] [Article Influence: 33.5] [Reference Citation Analysis]
36 Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23:652-658. [PMID: 21653683 DOI: 10.1093/annonc/mdr279] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
37 Aparo S, Goel S. Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol 2012;83:47-58. [PMID: 21944740 DOI: 10.1016/j.critrevonc.2011.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
38 Barreto R, Kitase Y, Matsumoto T, Pin F, Colston KC, Couch KE, O'Connell TM, Couch ME, Bonewald LF, Bonetto A. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci Rep 2017;7:14470. [PMID: 29089584 DOI: 10.1038/s41598-017-15040-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
39 Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D’Argento E, Trigila N, Astone A, Pozzo C. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035-1039. [PMID: 17895897 DOI: 10.1038/sj.bjc.6603988] [Cited by in Crossref: 95] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
40 Matsunaga M, Miwa K, Oka Y, Nagasu S, Sakaue T, Fukahori M, Ushijima T, Akagi Y. Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab. Case Rep Oncol 2016;9:249-54. [PMID: 27239180 DOI: 10.1159/000446107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
41 Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R, Ceciarini F, Micheli L, Nencini C, Neri A, Vuolo G, Guarnieri A, Abbruzzese A, Prete SD, Giorgi G, Francini G. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer 2004;90:1710-4. [PMID: 15150625 DOI: 10.1038/sj.bjc.6601783] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
42 Massmann A, Rodt T, Marquardt S, Seidel R, Thomas K, Wacker F, Richter GM, Kauczor HU, Bücker A, Pereira PL, Sommer CM. Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review. Langenbecks Arch Surg 2015;400:641-59. [PMID: 26088872 DOI: 10.1007/s00423-015-1308-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
43 Gherman A, Căinap C, Constantin AM, Cetean S, Căinap SS. Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Clujul Med 2017;90:377-84. [PMID: 29151784 DOI: 10.15386/cjmed-745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
44 Poultsides GA, Paty PB. Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective. Ther Adv Med Oncol. 2011;3:35-42. [PMID: 21789154 DOI: 10.1177/1758834010386283] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
45 Soerjomataram I, Thong MS, Korfage IJ, Polinder S, van der Heide A, de Vries E, Rietjens JA, Otto SJ, van de Poll-Franse LV. Excess weight among colorectal cancer survivors: target for intervention. J Gastroenterol 2012;47:999-1005. [PMID: 22426635 DOI: 10.1007/s00535-012-0567-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
46 Aranda E, Aparicio J, Alonso V, Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera R, Vieitez JM, Garcia-Carbonero R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol 2015;17:972-81. [PMID: 26669312 DOI: 10.1007/s12094-015-1434-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
47 Spiliopoulou P, Arkenau HT. Rationally designed treatment for metastatic colorectal cancer: current drug development strategies. World J Gastroenterol 2014;20:10288-95. [PMID: 25132745 DOI: 10.3748/wjg.v20.i30.10288] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Yasui H, Muro K, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Esaki T, Tokunaga S, Kuwano H, Boku N, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K. A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. J Cancer Res Clin Oncol 2015;141:153-60. [PMID: 25106731 DOI: 10.1007/s00432-014-1783-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
49 Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol 2009;63:441-50. [PMID: 18414865 DOI: 10.1007/s00280-008-0754-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
50 Tzeng CW, Aloia TA. Colorectal liver metastases. J Gastrointest Surg. 2013;17:195-201; quiz 201-202. [PMID: 23054896 DOI: 10.1007/s11605-012-2] [Reference Citation Analysis]
51 Hsu HC, Liu YS, Tseng KC, Hsu CL, Liang Y, Yang TS, Chen JS, Tang RP, Chen SJ, Chen HC. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis. 2013;28:1535-1546. [PMID: 23784051 DOI: 10.1007/s00384-013-1721-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
52 Moiseenko F, Volkov N, Bogdanov A, Dubina M, Moiseyenko V. Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion. F1000Res 2017;6:288. [PMID: 28751966 DOI: 10.12688/f1000research.10992.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
53 Wu Y, Dong G, Sheng C. Targeting necroptosis in anticancer therapy: mechanisms and modulators. Acta Pharm Sin B 2020;10:1601-18. [PMID: 33088682 DOI: 10.1016/j.apsb.2020.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
54 Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol 2015;33:22-8. [PMID: 25385741 DOI: 10.1200/JCO.2014.56.5887] [Cited by in Crossref: 67] [Cited by in F6Publishing: 22] [Article Influence: 9.6] [Reference Citation Analysis]
55 Gao J, Zhou J, Li Y, Peng Z, Li Y, Wang X, Shen L. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Med Oncol 2013;30:630. [PMID: 23783485 DOI: 10.1007/s12032-013-0630-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
56 Madi A, Fisher D, Wilson RH, Adams RA, Meade AM, Kenny SL, Nichols LL, Seymour MT, Wasan H, Kaplan R. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer. 2012;107:1037-1043. [PMID: 22935584 DOI: 10.1038/bjc.2012.384] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
57 Claassen YH, van der Valk MJ, Breugom AJ, Frouws MA, Bastiaannet E, Liefers GJ, van de Velde CJ, Kapiteijn E. Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. Cochrane Database Syst Rev 2018;11:CD012326. [PMID: 30480771 DOI: 10.1002/14651858.CD012326.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Stelzner S, Hellmich G, Jackisch T, Ludwig K, Witzigmann H. Selective surgical treatment of patients with rectal carcinoma and unresectable synchronous metastases based on response to preoperative chemotherapy. J Gastrointest Surg. 2008;12:1246-1250. [PMID: 18340498 DOI: 10.1007/s11605-008-0506-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
59 Legué LM, Bernards N, Lemmens VE, de Hingh IH, Creemers GJ, van Erning FN. Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice. United European Gastroenterol J 2019;7:1380-8. [PMID: 31839964 DOI: 10.1177/2050640619858211] [Reference Citation Analysis]
60 Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, Colucci G, Gerunda GE, Depenni R, Zironi S. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer. 2011;104:1079-1084. [PMID: 21386839 DOI: 10.1038/bjc.2011] [Reference Citation Analysis]
61 Kim IH, Lee JE, Yang JH, Jeong JW, Ro S, Oh ST, Kim JG, Choi MH, Lee MA. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer. Cancer Res Treat 2018;50:283-92. [PMID: 28494536 DOI: 10.4143/crt.2016.537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther 2015;16:1710-9. [PMID: 26561209 DOI: 10.1080/15384047.2015.1113355] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
63 Arnold D, Stein A. New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy. Drugs. 2013;73:883-891. [PMID: 23743737 DOI: 10.1007/s40265-013-0076-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
64 Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L, Capanu M, Yaeger R. Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clin Cancer Res 2017;23:4753-60. [PMID: 28446505 DOI: 10.1158/1078-0432.CCR-17-0400] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
65 Blackham AU, Swett K, Levine EA, Shen P. Surgical management of colorectal cancer metastases to the liver: multimodality approach and a single institutional experience. Colorectal Cancer 2013;2:73-88. [PMID: 25110522 DOI: 10.2217/crc.12.80] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
66 Recchia F, Saggio G, Nuzzo A, Lalli A, Lullo LD, Cesta A, Rea S. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer. 2004;91:1442-1446. [PMID: 15467766 DOI: 10.1038/sj.bjc.6602194] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
67 Palshof JA, Cederbye CN, Høgdall EVS, Poulsen TS, Linnemann D, Nygaard SB, Stenvang J, Christensen IJ, Jensen BV, Pfeiffer P, Brünner N, Yilmaz M, Viuff BM, Nielsen DL. ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. Int J Mol Sci 2020;21:E5027. [PMID: 32708825 DOI: 10.3390/ijms21145027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
68 Lin YL, Liang YH, Tsai JH, Liau JY, Liang JT, Lin BR, Hung JS, Lin LI, Tseng LH, Chang YL, Yeh KH, Cheng AL. Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients. PLoS One 2014;9:e86789. [PMID: 24505265 DOI: 10.1371/journal.pone.0086789] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
69 Noel MS. Biologics in bowel cancer. J Gastrointest Oncol 2017;8:449-56. [PMID: 28736632 DOI: 10.21037/jgo.2017.05.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Matsumoto Y, Saito M, Saito K, Kanke Y, Watanabe Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Kumamoto K, Ohki S, Takenoshita S. Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis. Oncol Lett 2018;15:2188-94. [PMID: 29434924 DOI: 10.3892/ol.2017.7555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
71 Ciombor KK, Bekaii-Saab T. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Oncologist 2018;23:25-34. [PMID: 29021377 DOI: 10.1634/theoncologist.2017-0203] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
72 Herrera M, Herrera A, Domínguez G, Silva J, García V, García JM, Gómez I, Soldevilla B, Muñoz C, Provencio M, Campos-Martin Y, García de Herreros A, Casal I, Bonilla F, Peña C. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci 2013;104:437-44. [PMID: 23298232 DOI: 10.1111/cas.12096] [Cited by in Crossref: 159] [Cited by in F6Publishing: 147] [Article Influence: 19.9] [Reference Citation Analysis]
73 Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother 2018;41:284-91. [PMID: 29668571 DOI: 10.1097/CJI.0000000000000222] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
74 Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017;109. [PMID: 28376151 DOI: 10.1093/jnci/djx015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 143] [Article Influence: 49.3] [Reference Citation Analysis]
75 Li F, Zhan L, Dong Q, Wang Q, Wang Y, Li X, Zhang Y, Zhang J. Tumor-Derived Exosome-Educated Hepatic Stellate Cells Regulate Lactate Metabolism of Hypoxic Colorectal Tumor Cells via the IL-6/STAT3 Pathway to Confer Drug Resistance. Onco Targets Ther 2020;13:7851-64. [PMID: 32821126 DOI: 10.2147/OTT.S253485] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Zhu GQ, You J, Shi KQ, He SY, Wang LR, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases. Medicine (Baltimore) 2015;94:e379. [PMID: 25569666 DOI: 10.1097/MD.0000000000000379] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
77 Kim KY, Kim NK, Cha IH, Ahn JB, Choi JS, Choi GH, Lim JS, Lee KY, Baik SH, Min BS, Hur H, Roh JK, Shin SJ. Novel methods for clinical risk stratification in patients with colorectal liver metastases. Cancer Res Treat 2015;47:242-50. [PMID: 25483744 DOI: 10.4143/crt.2014.066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
78 Sugimoto S, Katano K, Kanazawa A, Yoshimura H, Kidani A, Takeda H, Makino M, Ozaki N, Tanaka T, Ikeguchi M. Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. J Exp Clin Cancer Res 2009;28:109. [PMID: 19664225 DOI: 10.1186/1756-9966-28-109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
79 Kawai S, Takeshima N, Hayasaka Y, Notsu A, Yamazaki M, Kawabata T, Yamazaki K, Mori K, Yasui H. Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. BMC Cancer 2021;21:116. [PMID: 33541293 DOI: 10.1186/s12885-021-07823-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Yoshino T, Yamazaki K, Yamaguchi K, Doi T, Boku N, Machida N, Onozawa Y, Asayama M, Fujino T, Ohtsu A. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Invest New Drugs 2013;31:910-7. [PMID: 23179335 DOI: 10.1007/s10637-012-9895-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
81 Ta LE, Schmelzer JD, Bieber AJ, Loprinzi CL, Sieck GC, Brederson JD, Low PA, Windebank AJ. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One 2013;8:e54161. [PMID: 23326593 DOI: 10.1371/journal.pone.0054161] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
82 López RI, Castro JL, Cedeño H, Cisneros D, Corrales L, González-Herrera I, Lima-Pérez M, Prestol R, Salinas R, Soriano-García JL, T Zavala A, Zetina LM, Zúñiga-Orlich CE. Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016. ESMO Open 2018;3:e000315. [PMID: 29636987 DOI: 10.1136/esmoopen-2017-000315] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
83 Gallinger S, Biagi JJ, Fletcher GG, Nhan C, Ruo L, McLeod RS. Liver resection for colorectal cancer metastases. Curr Oncol. 2013;20:e255-e265. [PMID: 23737695 DOI: 10.3747/co.20.1341] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
84 Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2019;5:343-350. [PMID: 30476968 DOI: 10.1001/jamaoncol.2018.5080] [Cited by in Crossref: 88] [Cited by in F6Publishing: 61] [Article Influence: 44.0] [Reference Citation Analysis]
85 Mizushima T, Nomura M, Fujii M, Akamatsu H, Mizuno H, Tominaga H, Hasegawa J, Nakajima K, Yasumasa K, Yoshikawa M, Nishida T. Primary colorectal signet-ring cell carcinoma: clinicopathological features and postoperative survival. Surg Today. 2010;40:234-238. [PMID: 20180076 DOI: 10.1007/s00595-009-4057-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
86 Sharma V, Sharma A, Raina V, Dabkara D, Mohanti BK, Shukla NK, Pathy S, Thulkar S, Deo SVS, Kumar S, Sahoo RK. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center. BMC Cancer 2021;21:630. [PMID: 34049505 DOI: 10.1186/s12885-021-08398-z] [Reference Citation Analysis]
87 Yamashita Y, Adachi E, Toh Y, Ohgaki K, Ikeda O, Oki E, Minami K, Sakaguchi Y, Tsujita E, Okamura T. Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases. Surg Today 2011;41:526-32. [PMID: 21431486 DOI: 10.1007/s00595-010-4471-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
88 Hsu HC, Liu YC, Wang CW, Chou WC, Hsu YJ, Chiang JM, Lin YC, Yang TS. Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer. Cancer Med 2019;8:3437-46. [PMID: 31090176 DOI: 10.1002/cam4.2235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
89 Ronnekleiv-Kelly SM, Kennedy GD. Management of stage IV rectal cancer: palliative options. World J Gastroenterol. 2011;17:835-847. [PMID: 21412493 DOI: 10.3748/wjg.v17.i7.835] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
90 Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H. Is there diversity among UGT1A1 polymorphism in Japan? World J Gastrointest Oncol 2012;4:170-5. [PMID: 22848786 DOI: 10.4251/wjgo.v4.i7.170] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
91 McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68:487-506. [PMID: 18318567 DOI: 10.2165/00003495-200868040-00009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
92 Vikram R, Iyer RB. PET/CT imaging in the diagnosis, staging, and follow-up of colorectal cancer. Cancer Imaging 2008;8 Spec No A:S46-51. [PMID: 18852081 DOI: 10.1102/1470-7330.2008.9009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
93 Pereira PL. Actual role of radiofrequency ablation of liver metastases. Eur Radiol 2007;17:2062-70. [PMID: 17429644 DOI: 10.1007/s00330-007-0587-0] [Cited by in Crossref: 73] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
94 Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, Miller F, Ryu RK, Ibrahim S, Sato KT. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci. 2008;53:2556-2563. [PMID: 18231857 DOI: 10.1007/s10620-007-0148-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
95 Tsoulfas G, Pramateftakis MG. Management of rectal cancer and liver metastatic disease: which comes first? Int J Surg Oncol. 2012;2012:196908. [PMID: 22778934 DOI: 10.1155/2012/196908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
96 Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G. A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers (Basel). 2019;11. [PMID: 30691222 DOI: 10.3390/cancers11020147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
97 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Reference Citation Analysis]
98 de Mestier L, Manceau G, Neuzillet C, Bachet JB, Spano JP, Kianmanesh R, Vaillant JC, Bouché O, Hannoun L, Karoui M. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World J Gastrointest Oncol 2014;6:156-69. [PMID: 24936226 DOI: 10.4251/wjgo.v6.i6.156] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
99 Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005;5:116. [PMID: 16168057 DOI: 10.1186/1471-2407-5-116] [Cited by in Crossref: 106] [Cited by in F6Publishing: 83] [Article Influence: 6.6] [Reference Citation Analysis]
100 Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 2009;9:156. [PMID: 19457245 DOI: 10.1186/1471-2407-9-156] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
101 Bouchahda M, Macarulla T, Liedo G, Lévi F, Elez ME, Paule B, Karaboué A, Artru P, Tabernero J, Machover D, Innominato P, Goldschmidt E, Bonnet D, Ducreux M, Castagne V, Guimbaud R. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011;28 Suppl 1:S253-8. [PMID: 21053102 DOI: 10.1007/s12032-010-9716-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
102 Komori H, Beppu T, Baba Y, Horino K, Imsung C, Masuda T, Hayashi H, Okabe H, Ootao R, Watanabe M, Takamori H, Iyama K, Baba H. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. Int J Clin Oncol 2010;15:263-70. [DOI: 10.1007/s10147-010-0046-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
103 Chiorean EG, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, Croitoru AE, Grover S, Lohar PV, Odhiambo A, Park SH, Garcia ER, Teh C, Rose A, Zaki B, Chamberlin MD. Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.JCO Glob Oncol. 2020;6:414-438. [PMID: 32150483 DOI: 10.1200/JGO.19.00367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 19.0] [Reference Citation Analysis]
104 van der Pool AE, Lalmahomed ZS, de Wilt JH, Eggermont AM, Ijzermans JM, Verhoef C. Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy. J Gastrointest Surg 2009;13:890-5. [PMID: 19132450 DOI: 10.1007/s11605-008-0794-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
105 Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR. Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther 2007;14:139-50. [PMID: 17139321 DOI: 10.1038/sj.cgt.7700988] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
106 Takeuchi N, Koike K, Yoshida S, Kudo A, Sekiguchi N, Nakayama A, Kubota K, Rokuhara T, Kitahara M. Treatment of metastatic refractory colorectal cancer following regorafenib failure. Mol Clin Oncol 2017;7:308-12. [PMID: 28781808 DOI: 10.3892/mco.2017.1307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Holt PR, Kozuch P, Mewar S. Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. Best Pract Res Clin Gastroenterol. 2009;23:889-907. [PMID: 19942166 DOI: 10.1016/j.bpg.2009.10.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
108 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Sakuyama N, Sato T, Kishine K, Abe Y, Nagaoka I. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett. 2019;17:1842-1850. [PMID: 30675246 DOI: 10.3892/ol.2017.6960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
109 Wang T, Chen Z, Zhu Y, Pan Q, Liu Y, Qi X, Jin L, Jin J, Ma X, Hua D. Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells. J Biol Chem. 2015;290:448-456. [PMID: 25404731 DOI: 10.1074/jbc.m114.590364] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
110 Zervoudakis A, Boucher T, Kemeny NE. Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion. Visc Med 2017;33:47-53. [PMID: 28612017 DOI: 10.1159/000454693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
111 García-Carbonero R, Gómez España MA, Casado Sáenz E, Alonso Orduña V, Cervantes Ruipérez A, Gallego Plazas J, García Alfonso P, Juez Martel I, González Flores E, Lomas Garrido M, Isla Casado D; SEOM (Spanish Society for Medical Oncology). SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clin Transl Oncol 2010;12:729-34. [PMID: 20974564 DOI: 10.1007/s12094-010-0587-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
112 Dominic JL, Feroz SH, Muralidharan A, Ahmed A, Thirunavukarasu P. Aberrant Partial Chromosomal Instability With Chemotherapeutically Resistant Metachronous Colorectal Cancer Following a Synchronous Primary Colorectal Cancer: A Case Report. Cureus 2020;12:e11308. [PMID: 33282585 DOI: 10.7759/cureus.11308] [Reference Citation Analysis]
113 Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011;18:18-25. [PMID: 21331278 DOI: 10.3747/co.v18i1.708] [Cited by in Crossref: 188] [Cited by in F6Publishing: 154] [Article Influence: 18.8] [Reference Citation Analysis]
114 Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med. 2011;9:10. [PMID: 21281463 DOI: 10.1186/1741-7015-9-10] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
115 Li W, Xu J, Shen L, Liu T, Guo W, Zhang W, Chen Z, Zhu X, Li J. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer 2014;14:986. [PMID: 25527007 DOI: 10.1186/1471-2407-14-986] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
116 Hess LM, Cui ZL, Mytelka DS, Han Y, Goodloe R, Schelman W. Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA. Int J Colorectal Dis 2019;34:581-8. [PMID: 30623219 DOI: 10.1007/s00384-018-03227-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
117 De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, Toffoli G. Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Front Pharmacol 2018;9:367. [PMID: 29706892 DOI: 10.3389/fphar.2018.00367] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
118 Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009;27:2848-2854. [PMID: 19380443 DOI: 10.1200/jco.2008.20.4552] [Cited by in Crossref: 46] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
119 Symonds LK, Cohen SA. Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. Gastroenterol Rep (Oxf) 2019;7:301-11. [PMID: 31687149 DOI: 10.1093/gastro/goz035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
120 Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009;27:1948-55. [PMID: 19255311 DOI: 10.1200/JCO.2008.20.2879] [Cited by in Crossref: 114] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
121 Yuan M, Wang Z, Zhao Y, Feng T, Lv W, Zhong H. Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital. Front Pharmacol 2021;12:632076. [PMID: 34122063 DOI: 10.3389/fphar.2021.632076] [Reference Citation Analysis]
122 Nakanishi K, Kobayashi D, Mochizuki Y, Ishigure K, Ito S, Kojima H, Ishiyama A, Fujitake S, Shikano T, Morita S, Kodera Y. Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701). Int J Clin Oncol 2016;21:557-65. [PMID: 26547424 DOI: 10.1007/s10147-015-0919-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
123 Konishi T, Yoshidome H, Shimizu H, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takano S, Miyazaki M, Ohtsuka M. Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases. World J Surg Oncol 2020;18:139. [PMID: 32576191 DOI: 10.1186/s12957-020-01918-4] [Reference Citation Analysis]
124 Skeberdytė A, Sarapinienė I, Aleksander-Krasko J, Stankevičius V, Sužiedėlis K, Jarmalaitė S. Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines. Sci Rep 2018;8:17744. [PMID: 30531808 DOI: 10.1038/s41598-018-35815-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
125 Guo JH, Zhang HY, Gao S, Zhang PJ, Li XT, Chen H, Wang XD, Zhu X. Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. World J Gastroenterol. 2017;23:1406-1411. [PMID: 28293087 DOI: 10.3748/wjg.v23.i8.1406] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
126 Mahipal A, Shibata D, Siegel E, Springett G, Almhanna K, Fulp W, Williams-Elson I, Kim R. Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. Invest New Drugs 2015;33:1093-9. [PMID: 26275531 DOI: 10.1007/s10637-015-0277-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
127 Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol 2015;4:310-25. [PMID: 26816832 DOI: 10.3978/j.issn.2223-4683.2015.04.07] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
128 Wang DS, Hu MT, Wang ZQ, Ren C, Qiu MZ, Luo HY, Jin Y, Fong WP, Wang SB, Peng JW, Zou QF, Tan Q, Wang FH, Li YH. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open 2021;4:e215250. [PMID: 33835174 DOI: 10.1001/jamanetworkopen.2021.5250] [Reference Citation Analysis]
129 Paulatto L, Dioguardi Burgio M, Sartoris R, Beaufrère A, Cauchy F, Paradis V, Vilgrain V, Ronot M. Colorectal liver metastases: radiopathological correlation. Insights Imaging 2020;11:99. [PMID: 32844319 DOI: 10.1186/s13244-020-00904-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
130 Parmar A, Chan KKW, Ko YJ. Metastatic colorectal cancer: therapeutic options for treating refractory disease. Curr Oncol 2019;26:S24-32. [PMID: 31819707 DOI: 10.3747/co.26.5575] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
131 Garcia-Alfonso P, Muñoz-Martin A, Mendez-Ureña M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer 2009;101:1039-43. [PMID: 19738605 DOI: 10.1038/sj.bjc.6605261] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
132 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.4] [Reference Citation Analysis]
133 Morse MA. Adjuvant therapy of colon cancer: current status and future developments. Clin Colon Rectal Surg. 2005;18:224-231. [PMID: 20011305 DOI: 10.1055/s-2005-916283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
134 Mocellin S, Baretta Z, Roqué I Figuls M, Solà I, Martin-Richard M, Hallum S, Bonfill Cosp X. Second-line systemic therapy for metastatic colorectal cancer. Cochrane Database Syst Rev 2017;1:CD006875. [PMID: 28128439 DOI: 10.1002/14651858.CD006875.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
135 Doi T, Muro K, Yoshino T, Fuse N, Ura T, Takahari D, Feng HP, Shimamoto T, Noguchi K, Ohtsu A. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2013;72:643-52. [PMID: 23921573 DOI: 10.1007/s00280-013-2240-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
136 Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kimura K, Amano R, Hirakawa K, Ohira M. The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer. Oncol Lett 2018;16:666-72. [PMID: 29928454 DOI: 10.3892/ol.2018.8628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
137 Gan Z, Zou Q, Lin Y, Xu Z, Huang Z, Chen Z, Lv Y. Identification of a 13-gene-based classifier as a potential biomarker to predict the effects of fluorouracil-based chemotherapy in colorectal cancer. Oncol Lett. 2019;17:5057-5063. [PMID: 31186717 DOI: 10.3892/ol.2019.10159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Zhang Y, Zou JY, Wang Z, Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res. 2019;11:7787-7803. [PMID: 31496821 DOI: 10.2147/cmar.s215533] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
139 Karadurmus N, Sahin U, Basgoz BB, Arpaci F, Demirer T. Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer. World J Transplant 2016;6:675-81. [PMID: 28058217 DOI: 10.5500/wjt.v6.i4.675] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
140 Kim ST, Kim TW, Kim KP, Kim TY, Han SW, Lee JY, Lim SH, Lee MY, Kim H, Park YS. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Res Treat 2015;47:790-5. [PMID: 25672574 DOI: 10.4143/crt.2014.126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
141 Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 2015;33:1112-8. [PMID: 25691669 DOI: 10.1200/JCO.2014.58.4904] [Cited by in Crossref: 97] [Cited by in F6Publishing: 44] [Article Influence: 16.2] [Reference Citation Analysis]
142 Oliver Metzig M, Fuchs D, Tagscherer KE, Gröne H, Schirmacher P, Roth W. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB. Oncogene 2016;35:3399-409. [DOI: 10.1038/onc.2015.398] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
143 Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist. 2011;16:1557-1564. [PMID: 22016477 DOI: 10.1634/theoncologist.2011-0141] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
144 Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014;16:363. [PMID: 24293074 DOI: 10.1007/s11912-013-0363-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
145 Mado K, Ishii Y, Mazaki T, Ushio M, Masuda H, Takayama T. A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection. World J Surg Oncol 2006;4:3. [PMID: 16417646 DOI: 10.1186/1477-7819-4-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K, Inoue M, Takahashi M, Takahashi S, Ishioka C. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. Int J Clin Oncol 2016;21:1091-101. [PMID: 27435270 DOI: 10.1007/s10147-016-1017-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
147 Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005;28:417-33. [PMID: 15853443 DOI: 10.2165/00002018-200528050-00005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
148 Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle. 2012;11:4203-4210. [PMID: 23095641 DOI: 10.4161/cc.22498] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
149 Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27:3379-84. [PMID: 19487380 DOI: 10.1200/JCO.2008.20.9817] [Cited by in Crossref: 260] [Cited by in F6Publishing: 90] [Article Influence: 21.7] [Reference Citation Analysis]
150 Leen E, Kumar S, Khan SA, Low G, Ong KO, Tait P, Averkiou M. Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors. World J Gastroenterol 2009;15:289-99. [PMID: 19140228 DOI: 10.3748/wjg.15.289] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
151 Maron SB, Xu J, Janjigian YY. Targeting EGFR in Esophagogastric Cancer. Front Oncol 2020;10:553876. [PMID: 33364187 DOI: 10.3389/fonc.2020.553876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW. Guidelines for resection of colorectal cancer liver metastases. Gut. 2006;55 Suppl 3:iii1-iii8. [PMID: 16835351 DOI: 10.1136/gut.2006.098053] [Cited by in Crossref: 131] [Cited by in F6Publishing: 154] [Article Influence: 8.7] [Reference Citation Analysis]
153 Watanabe Y, Saito M, Saito K, Matsumoto Y, Kanke Y, Onozawa H, Hayase S, Sakamoto W, Ishigame T, Momma T, Ohki S, Takenoshita S. Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncol Lett 2018;15:2756-62. [PMID: 29435001 DOI: 10.3892/ol.2017.7650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
154 Wang S, Wang L, Zhou Z, Deng Q, Li L, Zhang M, Liu L, Li Y. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. Sci Rep 2017;7:682. [PMID: 28386133 DOI: 10.1038/s41598-017-00839-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
155 Liang HL, Hu AP, Li SL, Liu JY. Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. Med Oncol 2014;31:976. [PMID: 24793617 DOI: 10.1007/s12032-014-0976-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
156 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013;15:106-15. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
157 Zhang Q, Liu RX, Chan KW, Hu J, Zhang J, Wei L, Tan H, Yang X, Liu H. Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells. J Exp Clin Cancer Res 2019;38:320. [PMID: 31324203 DOI: 10.1186/s13046-019-1314-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
158 Toumazis I, Kurt M, Toumazi A, Karacosta LG, Kwon C. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy Pract 2017;2:2381468317729650. [PMID: 30288431 DOI: 10.1177/2381468317729650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
159 Yu IS, Cheung WY. Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. Can J Gastroenterol Hepatol 2018;2018:9450754. [PMID: 30519549 DOI: 10.1155/2018/9450754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
160 Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther. 2014;7:1817-1828. [PMID: 25336973 DOI: 10.2147/OTT.S48409ott-7-1817] [Reference Citation Analysis]
161 Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J Jr, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 2011;105:1646-53. [PMID: 22027708 DOI: 10.1038/bjc.2011.438] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
162 Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. Int J Colorectal Dis 2010;25:1243-9. [PMID: 20574727 DOI: 10.1007/s00384-010-0996-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
163 El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 2015;16:1726-37. [PMID: 26553611 DOI: 10.1080/15384047.2015.1113356] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
164 Oki E, Ando K, Nakanishi R, Sugiyama M, Nakashima Y, Kubo N, Kudou K, Saeki H, Nozoe T, Emi Y, Maehara Y. Recent advances in treatment for colorectal liver metastasis. Ann Gastroenterol Surg 2018;2:167-75. [PMID: 29863162 DOI: 10.1002/ags3.12071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
165 Baba H, Yamada Y, Takahari D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. ESMO Open 2017;2:e000135. [PMID: 28761727 DOI: 10.1136/esmoopen-2016-000135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
166 Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: Metastases to a single organ. World J Gastroenterol. 2015;21:11767-11776. [PMID: 26557001 DOI: 10.3748/wjg.v21.i41.11767] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 76] [Article Influence: 20.8] [Reference Citation Analysis]
167 Worni M, Shah KN, Clary BM. Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment. Curr Oncol Rep. 2014;16:407. [PMID: 25129331 DOI: 10.1007/s11912-014-0407-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
168 Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P. Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. Onco Targets Ther. 2013;6:1761-1769. [PMID: 24348051 DOI: 10.2147/ott.s43828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
169 Letaief F, Nasri M, Ayadi M, Meddeb K, Mokrani A, Yahyaoui Y, Chraiet N, Raies H, Mezlini A. Potential predictive factors for pathologic complete response after the neoadjuvant treatment of rectal adenocarcinoma: a single center experience. Cancer Biol Med 2017;14:327-34. [PMID: 28884049 DOI: 10.20892/j.issn.2095-3941.2017.0037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Ta LE, Low PA, Windebank AJ. Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 2009;5:9. [PMID: 19245717 DOI: 10.1186/1744-8069-5-9] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
171 Sumransub N, Vantanasiri K, Prakash A, Lou E. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? Mol Ther Oncolytics 2021;22:1-12. [PMID: 34307839 DOI: 10.1016/j.omto.2021.05.001] [Reference Citation Analysis]
172 Leung U, Gönen M, Allen PJ, Kingham TP, DeMatteo RP, Jarnagin WR, D'Angelica MI. Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. Ann Surg 2017;265:158-65. [PMID: 28009741 DOI: 10.1097/SLA.0000000000001624] [Cited by in Crossref: 69] [Cited by in F6Publishing: 30] [Article Influence: 17.3] [Reference Citation Analysis]
173 Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006;95:131-8. [PMID: 16835584 DOI: 10.1038/sj.bjc.6603233] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
174 Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T, Toh Y, Hyodo I, Nishina T, Furuhata T. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2010;21:766-771. [PMID: 19828562 DOI: 10.1093/annonc/mdp371] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
175 Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Invest New Drugs. 2012;30:1501-1510. [PMID: 21567184 DOI: 10.1007/s10637-011-9683-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
176 Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol 2021;13:17588359211020547. [PMID: 34262614 DOI: 10.1177/17588359211020547] [Reference Citation Analysis]
177 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
178 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020;11:761-808. [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
179 Stenvang J, Budinská E, van Cutsem E, Bosman F, Popovici V, Brünner N. An Explorative Analysis of ABCG2/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial. Cancers (Basel) 2020;12:E977. [PMID: 32326511 DOI: 10.3390/cancers12040977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
180 Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, Watson AJ, Margison GP, Midgley R, Middleton MR. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer. 2008;98:1614-1618. [PMID: 18475294 DOI: 10.1038/sj.bjc.6604366] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
181 Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9. [PMID: 19707427 DOI: 10.2147/btt.s1519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
182 Marschner N, Frank M, Vach W, Ladda E, Karcher A, Winter S, Jänicke M, Trarbach T. Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS). Colorectal Dis 2019;21:816-26. [PMID: 30834622 DOI: 10.1111/codi.14600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Gan S, Wilson K, Hollington P. Surveillance of patients following surgery with curative intent for colorectal cancer. World J Gastroenterol 2007;13:3816-23. [PMID: 17657835 DOI: 10.3748/wjg.v13.i28.3816] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
184 Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol. 2010;11:1-13. [PMID: 20143276 DOI: 10.1007/s11864-010-0115-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
185 Pathak S, Poston GJ. Colorectal liver metastases; the current scenario. Indian J Surg Oncol 2010;1:350-5. [PMID: 22693391 DOI: 10.1007/s13193-011-0066-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
186 Kumamoto K, Kuwabara K, Tajima Y, Amano K, Hatano S, Ohsawa T, Okada N, Ishibashi K, Haga N, Ishida H. Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. Oncol Lett. 2012;3:983-989. [PMID: 22783377 DOI: 10.3892/ol.2012.598] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
187 Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014;20:4208-19. [PMID: 24764659 DOI: 10.3748/wjg.v20.i15.4208] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
188 Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol. 2015;20:767-775. [PMID: 25627820 DOI: 10.1007/s10147-015-0784-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
189 Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015;6:185-200. [PMID: 25830038 DOI: 10.3978/j.issn.2078-6891.2014.112] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
190 Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer. 2009;9:112. [PMID: 19366444 DOI: 10.1186/1471-2407-9-112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
191 Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel) 2014;6:1753-68. [PMID: 25256831 DOI: 10.3390/cancers6031753] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
192 Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 2013;15:483-91. [PMID: 23750490 DOI: 10.1111/j.1477-2574.2012.00607.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 83] [Article Influence: 13.2] [Reference Citation Analysis]
193 Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, Baba H, Haga N, Ishida H. Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett. 2013;6:648-654. [PMID: 24137384 DOI: 10.3892/ol.2013.1467] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
194 de Jong MC, van Vledder MG, Ribero D, Hubert C, Gigot JF, Choti MA, Schulick RD, Capussotti L, Dejong CH, Pawlik TM. Therapeutic efficacy of combined intraoperative ablation and resection for colorectal liver metastases: an international, multi-institutional analysis. J Gastrointest Surg 2011;15:336-44. [PMID: 21108017 DOI: 10.1007/s11605-010-1391-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
195 Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J. Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis. Oncotarget 2018;9:10272-83. [PMID: 29535805 DOI: 10.18632/oncotarget.23475] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
196 Yamada Y, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Kato K, Hamaguchi T, Shimada Y. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 2012;30:1690-6. [PMID: 21894500 DOI: 10.1007/s10637-011-9743-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
197 Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. Br J Cancer 2017;116:1279-86. [PMID: 28427088 DOI: 10.1038/bjc.2017.109] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
198 McRee AJ, Sanoff HK, Carlson C, Ivanova A, O'Neil BH. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Invest New Drugs 2015;33:1225-31. [PMID: 26490655 DOI: 10.1007/s10637-015-0298-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
199 Cao R, Zhang S, Ma D, Hu L. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med Oncol 2015;32:325. [PMID: 25481673 DOI: 10.1007/s12032-014-0325-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
200 Lam VW, Laurence JM, Pang T, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB (Oxford). 2014;16:101-108. [PMID: 23509899 DOI: 10.1111/hpb.12083] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
201 Yoshino T, Oki E, Nozawa H, Eguchi-Nakajima T, Taniguchi H, Morita S, Takenaka N, Ozawa D, Shirao K. Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. ESMO Open 2018;3:e000411. [PMID: 30167332 DOI: 10.1136/esmoopen-2018-000411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
202 Passardi A, Scarpi E, Tamberi S, Cavanna L, Tassinari D, Fontana A, Pini S, Bernardini I, Accettura C, Ulivi P, Frassineti GL, Amadori D. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. PLoS One 2015;10:e0134732. [PMID: 26244985 DOI: 10.1371/journal.pone.0134732] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
203 Wood JP, Smith AJ, Bowman KJ, Thomas AL, Jones GD. Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo. Cancer Med 2015;4:1309-21. [PMID: 26108357 DOI: 10.1002/cam4.477] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
204 Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist 2009;14:970-8. [PMID: 19828593 DOI: 10.1634/theoncologist.2009-0175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
205 Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer 2020;20:687. [PMID: 32703200 DOI: 10.1186/s12885-020-07186-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
206 PelvEx Collaborative . Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). BJS Open 2021;5:zrab029. [PMID: 34089596 DOI: 10.1093/bjsopen/zrab029] [Reference Citation Analysis]
207 Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154. [PMID: 22115124 DOI: 10.1186/1477-7819-9-154] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
208 Wang L, Hollenbeak CS, Stewart DB. Node yield and node involvement in young colon cancer patients: is there a difference in cancer survival based on age? J Gastrointest Surg 2010;14:1355-61. [PMID: 20585992 DOI: 10.1007/s11605-010-1275-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
209 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Marusasa T, Hashiguchi T, Uchida T, Sakuyama N, Sato T, Kishine K, Futagawa S, Nagaoka I. Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer. Oncol Lett 2011;2:309-13. [PMID: 22866082 DOI: 10.3892/ol.2011.251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
210 Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, Sobhani I, Bardier A, Moreau M, Brindel I, Seitz JF, Taieb J. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial. BMC Cancer 2015;15:511. [PMID: 26156156 DOI: 10.1186/s12885-015-1507-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
211 Bae SB, Lee NS, Kim HJ, Kim KH, Kim HJ, Kim CK, Lee KT, Park SK, Won JH, Hong DS, Park HS. A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer. Cancer Res Treat 2006;38:72-7. [PMID: 19771263 DOI: 10.4143/crt.2006.38.2.72] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
212 Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res. 2013;5:377-385. [PMID: 24399885 DOI: 10.2147/cmar.s47986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
213 Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Invest New Drugs 2014;32:561-8. [PMID: 24573743 DOI: 10.1007/s10637-014-0075-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
214 Kim ST, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer 2014;14:883. [PMID: 25424120 DOI: 10.1186/1471-2407-14-883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
215 Matsui T, Kitamura T, Ozawa H, Matsuguma H, Kotake K. Analysis of treatment that includes both hepatic and pulmonary resections for colorectal metastases. Surg Today 2014;44:702-11. [PMID: 24170275 DOI: 10.1007/s00595-013-0769-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
216 Bazarbashi S, Hakoun AM, Gad AM, Elshenawy MA, Aljubran A, Alzahrani AM, Eldali A. Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer. Curr Oncol 2019;26:e24-9. [PMID: 30853806 DOI: 10.3747/co.26.4217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
217 Martin LK, Cucci A, Wei L, Rose J, Blazer M, Schmidt C, Khabiri H, Bloomston M, Bekaii-Saab T. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer 2012;11:195-9. [PMID: 22277350 DOI: 10.1016/j.clcc.2011.12.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
218 Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 2017;9:551-64. [PMID: 28794806 DOI: 10.1177/1758834017714997] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 13.5] [Reference Citation Analysis]
219 Puia-Negulescu S, Lebossé F, Mabrut JY, Muller X, Rossignol G, Antonini T, Erard D, Radenne S, Guillet M, Souquet JC, Mohkam K, Lesurtel M. Liver Transplantation for Colorectal Liver Metastases: Current Management and Future Perspectives. Int J Mol Sci 2021;22:3093. [PMID: 33803503 DOI: 10.3390/ijms22063093] [Reference Citation Analysis]
220 Kim JW, Lee KW, Kim KP, Lee JH, Hong YS, Kim JE, Kim SY, Park SR, Nam BH, Cho SH, Chung IJ, Park YS, Oh HS, Lee MA, Kang HJ, Park YI, Song EK, Han HS, Lee KT, Shin DB, Kang JH, Zang DY, Kim JH, Kim TW. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. Oncologist 2017;22:293-303. [PMID: 28209749 DOI: 10.1634/theoncologist.2016-0166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
221 Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer 2015;112:313-8. [PMID: 25412235 DOI: 10.1038/bjc.2014.561] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
222 Glockzin G, Gerken M, Lang SA, Klinkhammer-Schalke M, Piso P, Schlitt HJ. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. BMC Cancer. 2014;14:807. [PMID: 25369730 DOI: 10.1186/1471-2407-14-807] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
223 de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010;28:460-465. [PMID: 20008641 DOI: 10.1200/jco.2009.23.1407] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
224 Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42. [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z] [Cited by in Crossref: 282] [Cited by in F6Publishing: 228] [Article Influence: 141.0] [Reference Citation Analysis]
225 Parodi L, Pickering E, Cisar LA, Lee D, Soufi-Mahjoubi R. Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer. Arch Drug Inf 2008;1:97-106. [PMID: 19639031 DOI: 10.1111/j.1753-5174.2008.00014.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
226 Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs 2015;33:977-84. [PMID: 26062928 DOI: 10.1007/s10637-015-0257-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
227 Pugashetti N, Yap SA, Lara PN Jr, Gandour-Edwards R, Dall'Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Can Urol Assoc J 2015;9:E204-7. [PMID: 26085880 DOI: 10.5489/cuaj.2447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
228 Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med 2016;5:676-83. [PMID: 26806397 DOI: 10.1002/cam4.635] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
229 Ishii G, Ishii T. Review of cancer-associated fibroblasts and their microenvironment in post-chemotherapy recurrence. Hum Cell 2020;33:938-45. [PMID: 32852669 DOI: 10.1007/s13577-020-00417-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Fernandes GDS, Braghiroli MI, Artioli M, Paterlini ACCR, Teixeira MC, Gumz BP, Girardi DDM, Braghiroli OFM, Costa FP, Hoff PM. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. J Gastrointest Cancer 2018;49:470-5. [PMID: 28884286 DOI: 10.1007/s12029-017-0001-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
231 Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013;5:221-234. [PMID: 23858331 DOI: 10.1177/1758834013485111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
232 Goldstein D, Mitchell P, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Clarke S. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer 2005;92:832-7. [PMID: 15756253 DOI: 10.1038/sj.bjc.6602426] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
233 Rathkopf D, Dickson MA, Feldman DR, Carvajal RD, Shah MA, Wu N, Lefkowitz R, Gonen M, Cane LM, Dials HJ. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res. 2009;15:7405-7411. [PMID: 19934304 DOI: 10.1158/1078-0432.CCR-09-1502] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
234 Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2011;8:332-8. [PMID: 21611115 DOI: 10.7150/ijms.8.332] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
235 Reinacher-Schick AC, Bechstein WO. [Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology]. Internist (Berl) 2007;48:51-8. [PMID: 17160665 DOI: 10.1007/s00108-006-1770-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
236 Buzzelli JN, Ouaret D, Brown G, Allen PD, Muschel RJ. Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance. Stem Cell Res. 2018;27:109-120. [PMID: 29414601 DOI: 10.1016/j.scr.2018.01.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
237 Shabaruddin FH, Elliott RA, Valle JW, Newman WG, Payne K. Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. Br J Cancer 2010;103:315-23. [PMID: 20661248 DOI: 10.1038/sj.bjc.6605766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
238 Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag 2009;5:229-38. [PMID: 19436599 DOI: 10.2147/tcrm.s3583] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
239 Jensen NF, Stenvang J, Beck MK, Hanáková B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, Tarpgaard LS, Hansen TP, Budinská E, Pfeiffer P, Bosman F, Tejpar S, Roth A, Delorenzi M, Andersen CL, Rømer MU, Brünner N, Moreira JM. Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Mol Oncol 2015;9:1169-85. [PMID: 25759163 DOI: 10.1016/j.molonc.2015.02.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 7.3] [Reference Citation Analysis]
240 Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013;108:1931-1935. [PMID: 23652302 DOI: 10.1038/bjc.2013.225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
241 Wang JJ, Wang X, Song YX, Zhao JH, Sun JX, Shi JX, Wu ZH, Wang ZN. Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer. Dis Markers 2019;2019:2587109. [PMID: 31275444 DOI: 10.1155/2019/2587109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
242 Chen YX, Yang Q, Kuang JJ, Chen SY, Wei Y, Jiang ZM, Xie DR. Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials. Gastroenterol Res Pract 2014;2014:594930. [PMID: 24971091 DOI: 10.1155/2014/594930] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
243 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
244 Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, Punt CJ. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 2010;103:159-64. [PMID: 20551951 DOI: 10.1038/sj.bjc.6605737] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 7.4] [Reference Citation Analysis]
245 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Sakuyama N, Sato T, Kishine K, Abe Y, Nagaoka I. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2019;17:1842-50. [PMID: 30675246 DOI: 10.3892/ol.2018.9805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
246 Lu W, Fu D, Kong X, Huang Z, Hwang M, Zhu Y, Chen L, Jiang K, Li X, Wu Y, Li J, Yuan Y, Ding K. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms. Cancer Med 2020;9:1419-29. [PMID: 31893575 DOI: 10.1002/cam4.2786] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
247 Zheng Z, Hanna N, Onukwugha E, Reese ES, Seal B, Mullins CD. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Med 2014;3:124-33. [PMID: 24403130 DOI: 10.1002/cam4.176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
248 Lee HJ, Lee YS, Lee KW, Kim SY, Yoon CJ, Shin DY, Lee YG, Choi SY, Kang SG, Kang SB, Kim JH. Efficacy and safety of hepatic arterial infusion of fluorouracil with leucovorin as salvage treatment for refractory liver metastases from colorectal cancer. Korean J Intern Med 2011;26:82-8. [PMID: 21437167 DOI: 10.3904/kjim.2011.26.1.82] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
249 Feo L, Polcino M, Nash GM. Resection of the Primary Tumor in Stage IV Colorectal Cancer: When Is It Necessary? Surg Clin North Am. 2017;97:657-669. [PMID: 28501253 DOI: 10.1016/j.suc.2017.01.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
250 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF, Helmberger TK. [Developments and perspectives in radioablative techniques]. Radiologe. 2007;47:1083-1088. [PMID: 17943265 DOI: 10.1007/s00117-007-1572-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
251 Moriwaki T, Bando H, Takashima A, Yamazaki K, Esaki T, Yamashita K, Fukunaga M, Miyake Y, Katsumata K, Kato S, Satoh T, Ozeki M, Baba E, Yoshida S, Boku N, Hyodo I. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med Oncol 2012;29:2842-8. [PMID: 22209842 DOI: 10.1007/s12032-011-0151-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
252 Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011;8:210-5. [PMID: 21448307 DOI: 10.7150/ijms.8.210] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
253 Passot G, Chun YS, Kopetz SE, Overman MJ, Conrad C, Aloia TA, Vauthey JN. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol 2016;42:1378-84. [PMID: 27358198 DOI: 10.1016/j.ejso.2016.02.249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
254 Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. Int J Oncol 2014;44:17-26. [PMID: 24247407 DOI: 10.3892/ijo.2013.2179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
255 Wang Y, Yi C, Wang Y, Li H, Li B, Wang D, Du J, Liu L, Wang X. Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer. Oncol Lett 2017;14:5743-52. [PMID: 29113203 DOI: 10.3892/ol.2017.6933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
256 Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open 2017;2:e000147. [PMID: 28761730 DOI: 10.1136/esmoopen-2016-000147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
257 Freidlin B, Allegra CJ, Korn EL. Moving Molecular Profiling to Routine Clinical Practice: A Way Forward? J Natl Cancer Inst 2020;112:773-8. [PMID: 31868907 DOI: 10.1093/jnci/djz240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
258 Neugut AI, Becker DJ, Insel BJ, Hershman DL. Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer. J Oncol Pract 2012;8:156-63. [PMID: 22942809 DOI: 10.1200/JOP.2011.000371] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
259 Beretta GD, Petrelli F, Stinco S, Cabiddu M, Ghilardi M, Squadroni M, Borgonovo K, Barni S. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol. 2013;30:486. [PMID: 23400961 DOI: 10.1007/s12032-013-0486-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
260 Hayashi M, Inoue Y, Komeda K, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Okuda J, Takeshita A, Shibayama Y. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg. 2010;10:27. [PMID: 20875094 DOI: 10.1186/1471-2482-10-27] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
261 Zhao J, Li W, Zhu D, Yu Q, Zhang Z, Sun M, Cai S, Zhang W. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol 2014;31:802. [PMID: 24338217 DOI: 10.1007/s12032-013-0802-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
262 James MI, Iwuji C, Irving G, Karmokar A, Higgins JA, Griffin-Teal N, Thomas A, Greaves P, Cai H, Patel SR. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett. 2015;364:135-141. [PMID: 25979230 DOI: 10.1016/j.canlet.2015.05.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 14.7] [Reference Citation Analysis]
263 Sperling J, Brandhorst D, Schäfer T, Ziemann C, Benz-Weißer A, Scheuer C, Kollmar O, Schilling MK, Menger MD. Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clin Exp Metastasis 2013;30:447-55. [PMID: 23187934 DOI: 10.1007/s10585-012-9550-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
264 Baba K, Oshita A, Kohyama M, Inoue S, Kuroo Y, Yamaguchi T, Nakamura H, Sugiyama Y, Tazaki T, Sasaki M, Imamura Y, Daimaru Y, Ohdan H, Nakamitsu A. Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis. World J Gastroenterol. 2015;21:1982-1988. [PMID: 25684967 DOI: 10.3748/wjg.v21.i6.1982] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
265 Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013;7:637-646. [PMID: 23506979 DOI: 10.1016/j.molonc.2013.02.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
266 Tanaka T, Sato T, Nishiofuku H, Masada T, Tatsumoto S, Marugami N, Otsuji T, Kanno M, Koyama F, Sho M, Kichikawa K. Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. BMC Cancer 2019;19:758. [PMID: 31370815 DOI: 10.1186/s12885-019-5862-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
267 Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805. [PMID: 16508637 DOI: 10.1038/sj.bjc.6603011] [Cited by in Crossref: 246] [Cited by in F6Publishing: 182] [Article Influence: 16.4] [Reference Citation Analysis]
268 Semrad TJ, Fahrni AR, Gong IY, Khatri VP. Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings. Ann Surg Oncol 2015;22 Suppl 3:S855-62. [PMID: 26100816 DOI: 10.1245/s10434-015-4610-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
269 Mabro M, Artru P, André T, Flesch M, Maindrault-Goebel F, Landi B, Lledo G, Plantade A, Louvet C, de Gramont A. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006;94:1287-92. [PMID: 16622455 DOI: 10.1038/sj.bjc.6603095] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
270 Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O'Neil DS, Accordino MK, Kiran RP, Wright J, Hershman DL. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clin Colorectal Cancer. 2019;18:133-140. [PMID: 30878317 DOI: 10.1016/j.clcc.2019.01.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
271 Ungari AQ, Pereira LRL, Nunes AA, Peria FM. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school. BMC Cancer 2017;17:691. [PMID: 29041915 DOI: 10.1186/s12885-017-3679-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
272 Wilson PM, Fazzone W, LaBonte MJ, Deng J, Neamati N, Ladner RD. Novel opportunities for thymidylate metabolism as a therapeutic target. Mol Cancer Ther 2008;7:3029-37. [PMID: 18790783 DOI: 10.1158/1535-7163.MCT-08-0280] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
273 Lee MA, Byun JH, Shim BY, Woo IS, Kang JH, Hong YS, Lee KS, Choi MG, Chang SK, Oh ST, Choi SI, Lee DS. Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. Korean J Intern Med 2005;20:205-9. [PMID: 16295778 DOI: 10.3904/kjim.2005.20.3.205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
274 Takeshita N, Fukunaga T, Kimura M, Sugamoto Y, Tasaki K, Hoshino I, Ota T, Maruyama T, Tamachi T, Hosokawa T, Asai Y, Matsubara H. Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer. World J Gastroenterol 2015;21:12722-8. [PMID: 26640350 DOI: 10.3748/wjg.v21.i44.12722] [Cited by in CrossRef: 2] [Article Influence: 0.4] [Reference Citation Analysis]
275 Shinno Y, Goto Y, Watanabe S, Sato J, Morita R, Matsumoto Y, Murakami S, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO Open 2018;3:e000399. [PMID: 30559979 DOI: 10.1136/esmoopen-2018-000399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
276 Lin Z, Yang Y, Huang Y, Liang J, Lu F, Lao X. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis. Mol Clin Oncol 2015;3:959-67. [PMID: 26171215 DOI: 10.3892/mco.2015.572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
277 Hu YY, Kwok AC, Jiang W, Taback N, Loggers ET, Ting GV, Lipsitz SR, Weeks JC, Greenberg CC. High-cost imaging in elderly patients with stage IV cancer. J Natl Cancer Inst 2012;104:1164-72. [PMID: 22851271 DOI: 10.1093/jnci/djs286] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
278 Zeeshan MS, Ramzan Z. Current controversies and advances in the management of pancreatic adenocarcinoma. World J Gastrointest Oncol 2021;13:472-94. [PMID: 34163568 DOI: 10.4251/wjgo.v13.i6.472] [Reference Citation Analysis]
279 Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin Cancer Res. 2008;14:7074-7079. [PMID: 18981005 DOI: 10.1158/1078-0432.CCR-08-1014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
280 Aprile G, Lutrino SE, Ferrari L, Casagrande M, Bonotto M, Ongaro E, Puglisi F. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol. 2013;19:8474-8488. [PMID: 24379565 DOI: 10.3748/wjg.v19.i46.8474] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
281 Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer 2011;117:4484-92. [PMID: 21446046 DOI: 10.1002/cncr.26036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
282 Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol 2017;9:106-26. [PMID: 28203302 DOI: 10.1177/1758834016676703] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
283 Kobayashi H, Kotake K, Funahashi K, Hase K, Hirata K, Iiai T, Kameoka S, Kanemitsu Y, Maeda K, Murata A. Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol. 2014;49:646-654. [PMID: 23793379 DOI: 10.1007/s00535-013-0820-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
284 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207-239. [PMID: 25782566 DOI: 10.1007/s10147-015-0801-z] [Cited by in Crossref: 379] [Cited by in F6Publishing: 257] [Article Influence: 63.2] [Reference Citation Analysis]
285 Oppenheim DE, Spreafico R, Etuk A, Malone D, Amofah E, Peña-Murillo C, Murray T, McLaughlin L, Choi BS, Allan S, Belousov A, Passioukov A, Gerdes C, Umaña P, Farzaneh F, Ross P. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer 2014;110:1221-7. [PMID: 24496456 DOI: 10.1038/bjc.2014.35] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
286 Roh SA, Choi EY, Cho DH, Yoon YS, Kim TW, Kim YS, Kim JC. Characterization of biological responses of colorectal cancer cells to anticancer regimens. J Korean Surg Soc 2012;83:21-9. [PMID: 22792530 DOI: 10.4174/jkss.2012.83.1.21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
287 Juez I, Rubio C, Figueras J. Multidisciplinary approach of colorectal liver metastases. Clin Transl Oncol. 2011;13:721-727. [PMID: 21975333 DOI: 10.1007/s12094-011-0722-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
288 Amram ML, Montet X, Roth AD. Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer. Case Rep Oncol 2017;10:1029-34. [PMID: 29279709 DOI: 10.1159/000484401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Konopke R, Kersting S, Makowiec F, Gassmann P, Kuhlisch E, Senninger N, Hopt U, Saeger HD. Resection of colorectal liver metastases: is a resection margin of 3 mm enough? : a multicenter analysis of the GAST Study Group. World J Surg 2008;32:2047-56. [PMID: 18521661 DOI: 10.1007/s00268-008-9629-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
290 Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015;15:496. [PMID: 26141683 DOI: 10.1186/s12885-015-1503-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
291 Tampellini M, Saini A, Alabiso I, Bitossi R, Brizzi MP, Sculli CM, Berruti A, Gorzegno G, Magnino A, Sperti E, Miraglia S, Forti L, Alabiso O, Aglietta M, Harris A, Dogliotti L. The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. Br J Cancer 2006;95:13-20. [PMID: 16773070 DOI: 10.1038/sj.bjc.6603204] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
292 Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2014;8:59-67. [PMID: 24119443 DOI: 10.1016/j.molonc.2013.09.001] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 12.4] [Reference Citation Analysis]
293 Fujishima Y, Goi T, Kimura Y, Hirono Y, Katayama K, Yamaguchi A. MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer. Int J Oncol 2012;40:960-4. [PMID: 22266876 DOI: 10.3892/ijo.2012.1334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
294 Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, Giovannini I, Barone C. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11:318-324. [PMID: 17458605 DOI: 10.1007/s11605-006-0070-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
295 Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 2011;11:247. [PMID: 21669012 DOI: 10.1186/1471-2407-11-247] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
296 Treenert A, Areepium N, Tanasanvimon S. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy. Asian Pac J Cancer Prev 2018;19:2757-64. [PMID: 30360603 DOI: 10.22034/APJCP.2018.19.10.2757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
297 Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE, Ellis LM. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg 2005;241:748-56; discussion 756-8. [PMID: 15849510 DOI: 10.1097/01.sla.0000160699.59061.92] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
298 Ahmed S, Shahid RK, Leis A, Haider K, Kanthan S, Reeder B, Pahwa P. Should noncurative resection of the primary tumour be performed in patients with stage iv colorectal cancer? A systematic review and meta-analysis. Curr Oncol 2013;20:e420-41. [PMID: 24155639 DOI: 10.3747/co.20.1469] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
299 Nebuloni DR, Mak MP, Souza FH, Saragiotto DF, Júlio T, DE Castro G Jr, Sabbaga J, Hoff PM. Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis. Mol Clin Oncol 2013;1:175-9. [PMID: 24649143 DOI: 10.3892/mco.2012.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
300 Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009;115:3858-67. [PMID: 19517472 DOI: 10.1002/cncr.24428] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
301 Zhu J, Lian P, Liu F, Xu Y, Xu J, Guan Z, Liang L, Wang M, Cai S, Zhang Z. Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma. Radiat Oncol 2013;8:10. [PMID: 23295152 DOI: 10.1186/1748-717X-8-10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
302 Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057-1077. [PMID: 17530336 DOI: 10.1007/s11605-006-0061-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 123] [Article Influence: 10.8] [Reference Citation Analysis]
303 Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276-293. [PMID: 27482287 DOI: 10.1177/1758834016646734] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
304 Cercek A, Saltz L. Evolving treatment of advanced colorectal cancer. Curr Oncol Rep. 2010;12:153-159. [PMID: 20425074 DOI: 10.1007/s11912-010-0096-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
305 Yin J, Shen X, Li M, Ni F, Xu L, Lu H. miR-329 regulates the sensitivity of 5-FU in chemotherapy of colorectal cancer by targeting E2F1. Oncol Lett 2018;16:3587-92. [PMID: 30127965 DOI: 10.3892/ol.2018.9121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
306 Somarelli JA, Roghani RS, Moghaddam AS, Thomas BC, Rupprecht G, Ware KE, Altunel E, Mantyh JB, Kim SY, McCall SJ, Shen X, Mantyh CR, Hsu DS. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. Mol Cancer Ther 2020;19:2516-27. [PMID: 33158998 DOI: 10.1158/1535-7163.MCT-20-0454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
307 Cunningham D, Wong RP, D’Haens G, Douillard JY, Robertson J, Stone AM, Van Cutsem E on behalf of the HORIZON I study group. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br J Cancer. 2013;108:493-502. [PMID: 23299530 DOI: 10.1038/bjc.2012.545] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
308 Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol. 2016;8:642-655. [PMID: 27672422 DOI: 10.4251/wjgo.v8.i9.642] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 45] [Article Influence: 11.4] [Reference Citation Analysis]
309 Barone C, Landriscina M, Quirino M, Basso M, Pozzo C, Schinzari G, Di Leonardo G, D'Argento E, Trigila N, Cassano A. Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. Br J Cancer 2007;96:21-8. [PMID: 17164761 DOI: 10.1038/sj.bjc.6603496] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
310 Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol. 2007;25:773-780. [PMID: 17327601 DOI: 10.1200/jco.2006.07.4187] [Cited by in Crossref: 128] [Cited by in F6Publishing: 61] [Article Influence: 9.1] [Reference Citation Analysis]
311 Lin GN, Liu PP, Liu DY, Peng JW, Xiao JJ, Xia ZJ. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy. Chin J Cancer 2016;35:5. [PMID: 26740116 DOI: 10.1186/s40880-015-0063-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
312 Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 2013;109:401-7. [PMID: 23820256 DOI: 10.1038/bjc.2013.350] [Cited by in Crossref: 102] [Cited by in F6Publishing: 97] [Article Influence: 12.8] [Reference Citation Analysis]
313 Cotte E, Villeneuve L, Passot G, Boschetti G, Bin-Dorel S, Francois Y, Glehen O; French Research Group of Rectal Cancer Surgery (GRECCAR). GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. BMC Cancer 2015;15:47. [PMID: 25849254 DOI: 10.1186/s12885-015-1060-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
314 Chen EY, Blanke CD, Haller DG, Benson AB, Dragovich T, Lenz HJ, Robles C, Li H, Mori M, Mattek N, Sanborn RE, Lopez CD. A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 2018;41:1193-8. [PMID: 29782360 DOI: 10.1097/COC.0000000000000465] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
315 Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014;20:10316-30. [PMID: 25132748 DOI: 10.3748/wjg.v20.i30.10316] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
316 Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, Berg DJ, McLaughlin S, Redlinger M, Dorr A, Hambleton J, Holden S, Kearns A, Kenkare-Mitra S, Lum B, Meropol NJ, O'Dwyer PJ. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;65:97-105. [PMID: 19415281 DOI: 10.1007/s00280-009-1008-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
317 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
318 Inoue N, Ishida H, Sano M, Kishino T, Okada N, Kumamoto K, Ishibashi K. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol 2012;17:341-7. [PMID: 21833683 DOI: 10.1007/s10147-011-0298-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
319 Shimada H, Tanaka K, Endou I, Ichikawa Y. Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg. 2009;394:973-983. [PMID: 19582473 DOI: 10.1007/s00423-009-0530-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
320 Folprecht G. [Current medicinal treatment of metastasized colorectal carcinoma]. Chirurg. 2010;81:507-515. [PMID: 20574792 DOI: 10.1007/s00104-010-1892-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
321 Ogata Y, Tanaka T, Akagi Y, Ishibashi N, Tsuji Y, Matono K, Isobe M, Sueyoshi S, Kaibara A, Shirouzu K. Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer. Clin Med Insights Oncol. 2013;7:21-30. [PMID: 23439317 DOI: 10.4137/CMO.S10769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
322 Jia J, Zhang P, Gou M, Yang F, Qian N, Dai G. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. Dis Markers 2019;2019:6812045. [PMID: 30805037 DOI: 10.1155/2019/6812045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
323 Inoue Y, Hazama S, Suzuki N, Tokumitsu Y, Kanekiyo S, Tomochika S, Tsunedomi R, Tokuhisa Y, Iida M, Sakamoto K, Takeda S, Ueno T, Yoshino S, Nagano H. Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Sci 2017;108:455-60. [PMID: 28075526 DOI: 10.1111/cas.13162] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
324 Tampellini M, Brizzi MP, Bitossi R, Alabiso I, Sculli CM, Chiusa L, Papotti M, Dogliotti L. Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy. J Cancer Res Clin Oncol 2007;133:783-5. [PMID: 17551754 DOI: 10.1007/s00432-007-0234-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
325 Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: where to fit the target. World J Gastroenterol 2014;20:1993-2004. [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
326 Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453-459. [PMID: 20008624 DOI: 10.1200/jco.2009.24.8252] [Cited by in Crossref: 347] [Cited by in F6Publishing: 155] [Article Influence: 28.9] [Reference Citation Analysis]
327 Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol. 2010;16:3133-3143. [PMID: 20593498 DOI: 10.3748/wjg.v16.i25.3133] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
328 Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018;9:110-8. [PMID: 30254966 DOI: 10.5306/wjco.v9.i5.110] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
329 Nakashima-Nakasuga C, Hazama S, Suzuki N, Nakagami Y, Xu M, Yoshida S, Tomochika S, Fujiwara N, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Maeda N, Tsunedomi R, Iida M, Takeda S, Yoshino S, Ueno T, Hamamoto Y, Ogihara H, Hoshii Y, Nagano H. Serum LOX-1 is a novel prognostic biomarker of colorectal cancer. Int J Clin Oncol 2020;25:1308-17. [PMID: 32277394 DOI: 10.1007/s10147-020-01673-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
330 Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, Desramé J, Larsen AK, André T, Louvet C, de Gramont A. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist 2011;16:1228-38. [PMID: 21859820 DOI: 10.1634/theoncologist.2011-0039] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
331 Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012;48:997-1003. [PMID: 22445247 DOI: 10.1016/j.ejca.2012.02.056] [Cited by in Crossref: 85] [Cited by in F6Publishing: 72] [Article Influence: 9.4] [Reference Citation Analysis]
332 Aparicio J, Esposito F, Serrano S, Falco E, Escudero P, Ruiz-Casado A, Manzano H, Fernandez-Montes A. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. J Clin Med 2020;9:E3889. [PMID: 33265959 DOI: 10.3390/jcm9123889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
333 Shibutani M, Maeda K, Nagahara H, Fukuoka T, Iseki Y, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K, Ohira M. Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer. In Vivo 2018;32:151-8. [PMID: 29275313 DOI: 10.21873/invivo.11218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
334 Tarpgaard LS, Qvortrup C, Nygård SB, Nielsen SL, Andersen DR, Jensen NF, Stenvang J, Detlefsen S, Brünner N, Pfeiffer P. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. BMC Cancer 2016;16:91. [PMID: 26867764 DOI: 10.1186/s12885-016-2124-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
335 Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 2013;104:1662-9. [PMID: 24033692 DOI: 10.1111/cas.12283] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
336 Rocha LSDS, Riechelmann RP. Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges. Clinics (Sao Paulo) 2018;73:e542s. [PMID: 30281700 DOI: 10.6061/clinics/2018/e542s] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
337 Inoue Y, Hiro J, Toiyama Y, Tanaka K, Mohri Y, Kusunoki M. Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer. Oncol Lett 2012;3:363-8. [PMID: 22740912 DOI: 10.3892/ol.2011.508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
338 Nakagawa Y, Kuranaga Y, Tahara T, Yamashita H, Shibata T, Nagasaka M, Funasaka K, Ohmiya N, Akao Y. Induced miR-31 by 5-fluorouracil exposure contributes to the resistance in colorectal tumors. Cancer Sci 2019;110:2540-8. [PMID: 31162779 DOI: 10.1111/cas.14090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
339 Rosati G, Aprile G, Basile D, Avallone A. Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients. Front Oncol 2021;11:602596. [PMID: 33738249 DOI: 10.3389/fonc.2021.602596] [Reference Citation Analysis]
340 Kobayashi H, Kotake K, Sugihara K. Prognostic scoring system for stage IV colorectal cancer: is the AJCC sub-classification of stage IV colorectal cancer appropriate? Int J Clin Oncol. 2013;18:696-703. [PMID: 22692571 DOI: 10.1007/s10147-012-0433-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
341 Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S. Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Invest New Drugs. 2012;30:758-764. [PMID: 21057973 DOI: 10.1007/s10637-010-9575-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
342 Teng CL, Wang CY, Chen YH, Lin CH, Hwang WL. Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study. PLoS One 2015;10:e0135673. [PMID: 26273837 DOI: 10.1371/journal.pone.0135673] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
343 Tohme S, Sukato D, Nace GW, Zajko A, Amesur N, Orons P, Chalhoub D, Marsh JW, Geller DA, Tsung A. Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer. HPB (Oxford) 2014;16:1110-6. [PMID: 25123597 DOI: 10.1111/hpb.12307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
344 Ma WW, Saif MW, El-Rayes BF, Fakih MG, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamat MK. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017;123:345-356. [PMID: 27622829 DOI: 10.1002/cncr.30321] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 9.8] [Reference Citation Analysis]
345 Lin XB, Dieleman LA, Ketabi A, Bibova I, Sawyer MB, Xue H, Field CJ, Baracos VE, Gänzle MG. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS One 2012;7:e39764. [PMID: 22844397 DOI: 10.1371/journal.pone.0039764] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
346 Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. Cancer Sci 2019;110:1032-43. [PMID: 30657223 DOI: 10.1111/cas.13943] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
347 Tirumani SH, Kim KW, Nishino M, Howard SA, Krajewski KM, Jagannathan JP, Cleary JM, Ramaiya NH, Shinagare AB. Update on the role of imaging in management of metastatic colorectal cancer. Radiographics. 2014;34:1908-1928. [PMID: 25384292 DOI: 10.1148/rg.347130090] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
348 Otsuka K, Satoyoshi R, Nanjo H, Miyazawa H, Abe Y, Tanaka M, Yamamoto Y, Shibata H. Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis. Oncol Lett 2012;3:649-53. [PMID: 22740969 DOI: 10.3892/ol.2011.543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
349 Ahmad R, Singh JK, Wunnava A, Al-Obeed O, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). Int J Mol Med. 2021;47. [PMID: 33655327 DOI: 10.3892/ijmm.2021.4847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Huh JW, Park YA, Jung EJ, Lee KY, Kwon JE, Sohn SK. Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay. J Korean Med Sci 2008;23:916-9. [PMID: 18955806 DOI: 10.3346/jkms.2008.23.5.916] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
351 Goodwin RA, Asmis TR. Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg. 2009;22:251-256. [PMID: 21037816 DOI: 10.1055/s-0029-1242465] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
352 Zhang X, Zhang W, Cao P. Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies. Front Oncol 2021;11:629390. [PMID: 33718206 DOI: 10.3389/fonc.2021.629390] [Reference Citation Analysis]
353 Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Koisumi J. Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today 2013;43:1088-94. [PMID: 23143145 DOI: 10.1007/s00595-012-0416-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
354 Wehler TC, Cao Y, Galle PR, Theobald M, Moehler M, Schimanski CC. Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously. Oncol Lett 2012;3:1191-4. [PMID: 22783416 DOI: 10.3892/ol.2012.640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
355 Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol 2015;12:607-19. [PMID: 26215044 DOI: 10.1038/nrclinonc.2015.129] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 15.2] [Reference Citation Analysis]
356 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012;17:1-29. [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2] [Cited by in Crossref: 491] [Cited by in F6Publishing: 403] [Article Influence: 49.1] [Reference Citation Analysis]
357 Marsala A, Lee EW, Padia SA. Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy. Semin Intervent Radiol 2017;34:116-20. [PMID: 28579679 DOI: 10.1055/s-0037-1602711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
358 Cecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 2021;127:1417-24. [PMID: 33351187 DOI: 10.1002/cncr.33379] [Reference Citation Analysis]
359 Knowles B, Welsh FK, Chandrakumaran K, John TG, Rees M. Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. HPB (Oxford) 2012;14:298-309. [PMID: 22487067 DOI: 10.1111/j.1477-2574.2012.00447.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
360 Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573. [PMID: 19998273 DOI: 10.1002/cncr.24760] [Cited by in Crossref: 1205] [Cited by in F6Publishing: 993] [Article Influence: 109.5] [Reference Citation Analysis]
361 Seki K, Tsuduki Y, Ioroi T, Yamane M, Yamauchi H, Shiraishi Y, Ogawa T, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Yamamori M, Kuwahara A, Okamura N, Sakaeda T. Serum lactate dehydrogenase levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2014;11:641-5. [PMID: 24782655 DOI: 10.7150/ijms.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
362 Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Invest New Drugs. 2013;31:183-191. [PMID: 22782485 DOI: 10.1007/s10637-012-9853-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
363 Deng Y, Cai Y, Lin J, Jiang L, Hu H. Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence - A retrospective single-center study. Gastroenterol Rep (Oxf) 2015;3:339-43. [PMID: 26468218 DOI: 10.1093/gastro/gov051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
364 Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, Maggi C, Gariboldi M, Pierotti MA, Di Bartolomeo M, Sottotetti E, Mennitto R, Bossi I, de Braud F, Clementi E, Pietrantonio F. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol 2015;80:581-8. [PMID: 25782327 DOI: 10.1111/bcp.12631] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
365 Miwa K, Oki E, Emi Y, Saeki H, Kusumoto T, Akagi Y, Ogata Y, Samura H, Tokunaga S, Ishikawa H, Tanaka T, Sueyoshi S, Higashi H, Matsuda H, Touyama T, Maehara Y; Kyushu Study Group of Clinical Cancer. Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). Int J Clin Oncol 2016;21:110-7. [PMID: 26037783 DOI: 10.1007/s10147-015-0850-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Homayounfar K, Liersch T, Schuetze G, Niessner M, Goralczyk A, Meller J, Langer C, Ghadimi BM, Becker H, Lorf T. Two-stage hepatectomy (R0) with portal vein ligation--towards curing patients with extended bilobular colorectal liver metastases. Int J Colorectal Dis. 2009;24:409-418. [PMID: 19084973 DOI: 10.1007/s00384-008-0620-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
367 Wang ZQ, Zhang DS, Xu N, Luo DY, Deng YH, Wang FH, Luo HY, Qiu MZ, Li YH, Xu RH. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chin J Cancer 2016;35:8. [PMID: 26739998 DOI: 10.1186/s40880-015-0061-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
368 Eveno C, Karoui M, Gayat E, Luciani A, Auriault ML, Kluger MD, Baumgaertner I, Baranes L, Laurent A, Tayar C, Azoulay D, Cherqui D. Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections. HPB (Oxford) 2013;15:359-64. [PMID: 23458567 DOI: 10.1111/j.1477-2574.2012.00581.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
369 Tsoulfas G, Pramateftakis MG, Kanellos I. Surgical treatment of hepatic metastases from colorectal cancer. World J Gastrointest Oncol. 2011;3:1-9. [PMID: 21267397 DOI: 10.4251/wjgo.v3.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
370 Li J, Yu Q, Fu S, Xu M, Zhang T, Xie C, Feng J, Chen J, Zang A, Cai Y, Fu Q, Liu S, Zhang M, Hong Q, Huang L, Yuan X. A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. J Cancer Res Clin Oncol 2016;142:1621-8. [PMID: 27160286 DOI: 10.1007/s00432-016-2176-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
371 Yamauchi Y, Izumi Y, Kawamura M, Nakatsuka S, Yashiro H, Tsukada N, Inoue M, Asakura K, Nomori H. Percutaneous cryoablation of pulmonary metastases from colorectal cancer. PLoS One 2011;6:e27086. [PMID: 22096520 DOI: 10.1371/journal.pone.0027086] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
372 Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, Van Cutsem E. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer. 2013;109:1735-1743. [PMID: 24045663 DOI: 10.1038/bjc.2013.523] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
373 Shankaran V, Wisinski KB, Mulcahy MF, Benson AB 3rd. The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Mol Diagn Ther 2008;12:87-98. [PMID: 18422373 DOI: 10.1007/BF03256274] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
374 Jensen NF, Agama K, Roy A, Smith DH, Pfister TD, Rømer MU, Zhang HL, Doroshow JH, Knudsen BR, Stenvang J. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. J Exp Clin Cancer Res. 2016;35:56. [PMID: 27029323 DOI: 10.1186/s13046-016-0335-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
375 Moriwaki T, Gosho M, Sugaya A, Yamada T, Yamamoto Y, Hyodo I. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. Cancer Res Treat 2021;53:703-13. [PMID: 33285056 DOI: 10.4143/crt.2020.805] [Reference Citation Analysis]
376 Engel RM, Chan WH, Nickless D, Hlavca S, Richards E, Kerr G, Oliva K, McMurrick PJ, Jardé T, Abud HE. Patient-Derived Colorectal Cancer Organoids Upregulate Revival Stem Cell Marker Genes following Chemotherapeutic Treatment. J Clin Med 2020;9:E128. [PMID: 31906589 DOI: 10.3390/jcm9010128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
377 Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Br J Cancer. 2012;106:453-459. [PMID: 22240792 DOI: 10.1038/bjc.2011.594] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
378 McKeown E, Nelson DW, Johnson EK, Maykel JA, Stojadinovic A, Nissan A, Avital I, Brücher BL, Steele SR. Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer 2014;5:31-43. [PMID: 24396496 DOI: 10.7150/jca.7987] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
379 Basu S, Zeng M, Yin T, Gao S, Hu M. Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1015-1016:34-41. [PMID: 26894853 DOI: 10.1016/j.jchromb.2016.02.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
380 Chen J, Shao R, Li L, Xu ZP, Gu W. Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways. Int J Nanomedicine. 2014;9:3403-3411. [PMID: 25075187 DOI: 10.2147/ijn.s61633] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
381 Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol. 2007;13:3806-3815. [PMID: 17657834 DOI: 10.3748/wjg.v13.i28.3806] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
382 Sheikh HY, Valle JW, Waddell T, Palmer K, Wilson G, Sjursen A, Craven O, Swindell R, Saunders MP. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. Br J Cancer 2008;99:577-83. [PMID: 18682717 DOI: 10.1038/sj.bjc.6604499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
383 Lin YL, Liau JY, Yu SC, Tseng LH, Lin LI, Liang JT, Lin BR, Hung JS, Chang YL, Yeh KH, Cheng AL. Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. Transl Oncol 2013;6:363-9. [PMID: 23730417 DOI: 10.1593/tlo.13166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
384 Batra A, Rigo R, Sheka D, Cheung WY. Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. World J Gastrointest Oncol 2020;12:604-18. [PMID: 32699576 DOI: 10.4251/wjgo.v12.i6.604] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
385 Yamada K, Ozawa D, Onozato R, Suzuki M, Fujita A, Ojima H. Optimal timing for the resection of pulmonary metastases in patients with colorectal cancer. Medicine (Baltimore) 2020;99:e19144. [PMID: 32118717 DOI: 10.1097/MD.0000000000019144] [Reference Citation Analysis]
386 Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C. Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer. Cancer Sci 2021;112:1567-78. [PMID: 33548159 DOI: 10.1111/cas.14841] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
387 Patel GS, Karapetis CS. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res. 2013;5:387-400. [PMID: 24294007 DOI: 10.2147/cmar.s35025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
388 Angelsen JH, Viste A, Løes IM, Eide GE, Hoem D, Sorbye H, Horn A. Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World J Surg Oncol 2015;13:328. [PMID: 26631156 DOI: 10.1186/s12957-015-0738-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
389 Fujita K, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015;21:12234-48. [PMID: 26604633 DOI: 10.3748/wjg.v21.i43.12234] [Cited by in CrossRef: 114] [Cited by in F6Publishing: 85] [Article Influence: 22.8] [Reference Citation Analysis]
390 Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle. 2012;11:2518-2525. [PMID: 22751419 DOI: 10.4161/cc.20900] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
391 Misiakos EP, Karidis NP, Kouraklis G. Current treatment for colorectal liver metastases. World J Gastroenterol 2011;17:4067-75. [PMID: 22039320 DOI: 10.3748/wjg.v17.i36.4067] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 80] [Article Influence: 11.1] [Reference Citation Analysis]
392 Shibutani M, Maeda K, Nagahara H, Iseki Y, Hirakawa K, Ohira M. The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer. Springerplus 2016;5:1798. [PMID: 27812440 DOI: 10.1186/s40064-016-3529-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
393 Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am. 2017;26:667-687. [PMID: 28923224 DOI: 10.1016/j.soc.2017.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
394 Gorbunova V, Beck JT, Hofheinz RD, Garcia-Alfonso P, Nechaeva M, Cubillo Gracian A, Mangel L, Elez Fernandez E, Deming DA, Ramanathan RK, Torres AH, Sullivan D, Luo Y, Berlin JD. A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Br J Cancer 2019;120:183-9. [PMID: 30531832 DOI: 10.1038/s41416-018-0343-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
395 Kuboki Y, Mizunuma N, Ozaka M, Ogura M, Suenaga M, Shinozaki E, Matsusaka S, Chin K, Matsuura M, Hatake K. Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer. Oncol Lett 2011;2:493-8. [PMID: 22866109 DOI: 10.3892/ol.2011.260] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
396 de Gramont A, Tournigand C, Louvet C, Maindrault-Goebel F, André T. First-line therapy for advanced colorectal cancer. Curr Oncol Rep 2005;7:167-72. [PMID: 15847706 DOI: 10.1007/s11912-005-0069-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
397 Yu QQ, Qiu H, Zhang MS, Hu GY, Liu B, Huang L, Liao X, Li QX, Li ZH, Yuan XL. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy. World J Gastroenterol 2016;22:4250-8. [PMID: 27122675 DOI: 10.3748/wjg.v22.i16.4250] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
398 Siesing C, Sorbye H, Dragomir A, Pfeiffer P, Qvortrup C, Pontén F, Jirström K, Glimelius B, Eberhard J. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS One 2017;12:e0182512. [PMID: 28800641 DOI: 10.1371/journal.pone.0182512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
399 Skof E, Rebersek M, Hlebanja Z, Ocvirk J. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 2009;9:120. [PMID: 19386096 DOI: 10.1186/1471-2407-9-120] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
400 De Mattia E, Polesel J, Roncato R, Labriet A, Bignucolo A, Dreussi E, Romanato L, Guardascione M, Buonadonna A, D'Andrea M, Lévesque E, Jonker D, Couture F, Guillemette C, Cecchin E, Toffoli G. Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. Front Oncol 2019;9:1312. [PMID: 31850208 DOI: 10.3389/fonc.2019.01312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
401 Damianovich D, Adena M, Tebbutt NC. Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. Br J Cancer 2007;96:546-50. [PMID: 17285136 DOI: 10.1038/sj.bjc.6603590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
402 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
403 Aubin F, Gill S, Burkes R, Colwell B, Kamel-Reid S, Koski S, Pollett A, Samson B, Tehfe M, Wong R, Young S, Soulières D. Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. Curr Oncol 2011;18:e180-4. [PMID: 21874108 DOI: 10.3747/co.v18i4.779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
404 Cui D, Cao D, Yang Y, Qiu M, Huang Y, Yi C. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Mol Biol Rep 2014;41:1291-8. [PMID: 24390240 DOI: 10.1007/s11033-013-2974-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
405 Che J, Pan L, Yang X, Liu Z, Huang L, Wen C, Lin A, Liu H. Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis. Mol Clin Oncol. 2017;7:943-952. [PMID: 29285354 DOI: 10.3892/mco.2017.1436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
406 Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice. J Oncol Pract. 2010;6:301-307. [PMID: 21358960 DOI: 10.1200/jop.2010.000072] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
407 Song X, Zhao Z, Barber B, Gregory C, Schutt D, Gao S. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract 2011;7:25s-30s. [PMID: 21886516 DOI: 10.1200/JOP.2011.000304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
408 Leichman L, Groshen S, O’Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist. 2016;21:172-177. [PMID: 26786262 DOI: 10.1634/theoncologist.2015-0319] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
409 Zhang H, Guo J, Gao S, Zhang P, Chen H, Wang X, Li X, Zhu X. Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis. Chin J Cancer Res. 2017;29:36-44. [PMID: 28373752 DOI: 10.21147/j.issn.1000-9604.2017.01.05] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
410 Tsukioka T, Nishiyama N, Iwata T, Nagano K, Izumi N, Mizuguchi S, Morita R, Inoue K, Suehiro S. Pulmonary metastasis from colorectal carcinoma with hepatic metastasis. Gen Thorac Cardiovasc Surg 2007;55:455-60. [PMID: 18049853 DOI: 10.1007/s11748-007-0165-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
411 Ocean AJ, Polite B, Christos P, Horvath L, Hamilton A, Matulich D, Chen HX, Sparano JA, Kindler HL. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer 2010;9:290-6. [PMID: 21208843 DOI: 10.3816/CCC.2010.n.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
412 Choti MA. Liver-directed treatments for metastatic colorectal cancer. Curr Treat Options Oncol 2014;15:456-64. [PMID: 24952016 DOI: 10.1007/s11864-014-0297-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
413 Stanel SC, Sjöberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, Gravanis I, Tzogani K, Pignatti F. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open 2017;2:e000190. [PMID: 28761750 DOI: 10.1136/esmoopen-2017-000190] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
414 Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol 2008;9:357-74. [PMID: 19238551 DOI: 10.1007/s11864-009-0089-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
415 Uboha N, Hochster HS. TAS-102: a novel antimetabolite for the 21st century. Future Oncol 2016;12:153-63. [PMID: 26616466 DOI: 10.2217/fon.15.276] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
416 Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30:608-615. [PMID: 22253466 DOI: 10.1200/jco.2011.38.9650] [Cited by in Crossref: 93] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
417 Cao C, Zhang X, Kuang M, Gu D, He M, Chen J, Tang C. Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis. Cancer Sci 2014;105:1008-14. [PMID: 24974863 DOI: 10.1111/cas.12465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
418 Frank D, Jumonville A, Loconte NK, Schelman WR, Mulkerin D, Lubner S, Richter K, Winterle N, Wims MB, Dietrich L, Winkler JM, Volk M, Kim K, Holen KD. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. J Gastrointest Oncol 2012;3:90-6. [PMID: 22811876 DOI: 10.3978/j.issn.2078-6891.2011.049] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
419 Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296-1310. [PMID: 18471507 DOI: 10.1053/j.gastro.2008.02.098] [Cited by in Crossref: 307] [Cited by in F6Publishing: 240] [Article Influence: 23.6] [Reference Citation Analysis]
420 Zafar SY, Marcello JE, Wheeler JL, Rowe KL, Morse MA, Herndon JE, Abernethy AP. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 2009;5:228-33. [PMID: 20856733 DOI: 10.1200/JOP.091010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
421 Gavriilidis P, Tobias A, Sutcliffe RP, Azoulay D, Roberts KJ. Network Meta-Analysis of Adjuvant Chemotherapy following Resection of Colorectal Liver Metastases. Gastrointest Tumors 2018;5:21-31. [PMID: 30574478 DOI: 10.1159/000490763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
422 Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004;91:344-354. [PMID: 15213713 DOI: 10.1038/sj.bjc.6601975] [Cited by in Crossref: 288] [Cited by in F6Publishing: 235] [Article Influence: 16.9] [Reference Citation Analysis]
423 Sánchez-Gundín J, Fernández-Carballido AM, Martínez-Valdivieso L, Barreda-Hernández D, Torres-Suárez AI. New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer. Int J Med Sci 2018;15:659-65. [PMID: 29910669 DOI: 10.7150/ijms.24453] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
424 McCulloch M, Broffman M, van der Laan M, Hubbard A, Kushi L, Abrams DI, Gao J, Colford JM Jr. Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther 2011;10:240-59. [PMID: 21964510 DOI: 10.1177/1534735411406539] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
425 Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017;317:2392-2401. [PMID: 28632865 DOI: 10.1001/jama.2017.7105] [Cited by in Crossref: 334] [Cited by in F6Publishing: 249] [Article Influence: 83.5] [Reference Citation Analysis]
426 Ozcelik M, Odabas H, Ercelep O, Yuksel S, Mert AG, Aydin D, Surmeli H, Isik D, Isik S, Oyman A, Oven Ustaalioglu BB, Aliustaoglu M, Gumus M. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients. Clin Transl Oncol 2016;18:617-24. [PMID: 26459249 DOI: 10.1007/s12094-015-1408-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
427 Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 2010;14:375-84. [PMID: 21275455 DOI: 10.1007/BF03256395] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
428 Vijayvergia N, Li T, Wong YN, Hall MJ, Cohen SJ, Dotan E. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer 2016;122:3191-8. [PMID: 27379436 DOI: 10.1002/cncr.30077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
429 Leelakanok N, Geary S, Salem A. Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil. J Pharm Sci 2018;107:513-28. [PMID: 29045885 DOI: 10.1016/j.xphs.2017.10.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
430 Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics J 2018;18:623-32. [PMID: 29925895 DOI: 10.1038/s41397-018-0030-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
431 Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterol. 2015;15:37. [PMID: 25888291 DOI: 10.1186/s12876-015-0266-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
432 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 2015;9:3099-108. [PMID: 26124634 DOI: 10.2147/DDDT.S85567] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
433 Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Mol Cancer Ther 2012;11:1500-9. [PMID: 22351745 DOI: 10.1158/1535-7163.MCT-11-0937] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
434 Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 2017;23:4146-54. [PMID: 28280091 DOI: 10.1158/1078-0432.CCR-16-3138] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
435 Are C, Gonen M, Zazzali K, Dematteo RP, Jarnagin WR, Fong Y, Blumgart LH, D'Angelica M. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007;246:295-300. [PMID: 17667509 DOI: 10.1097/sla.0b013e31811ea962] [Cited by in Crossref: 164] [Cited by in F6Publishing: 64] [Article Influence: 11.7] [Reference Citation Analysis]
436 Takao M, Yamazaki K, Boku N, Ikehara H, Hamauchi S, Tsushima T, Taniguchi H, Todaka A, Machida N, Fukutomi A, Onozawa Y, Yasui H. Endoscopic evaluation of primary tumor response in patients with metastatic colorectal cancer treated by systemic chemotherapy. Int J Clin Oncol 2013;18:864-8. [PMID: 22865286 DOI: 10.1007/s10147-012-0452-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
437 Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 2007;97:1469-74. [PMID: 18040272 DOI: 10.1038/sj.bjc.6604053] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
438 El-Rayes BF, Zalupski MM, Manza SG, Rusin B, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Shields AF, Philip PA. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol 2008;61:283-9. [PMID: 17429629 DOI: 10.1007/s00280-007-0472-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
439 Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol 2019;26:S7-S15. [PMID: 31819705 DOI: 10.3747/co.26.5719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
440 Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics 2012;30:1119-32. [PMID: 23058097 DOI: 10.2165/11597210-000000000-00000] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
441 Ariyan CE, Salem RR. Evolution in the treatment of metastatic colorectal carcinoma of the liver. World J Gastroenterol 2006;12:3253-8. [PMID: 16718848 DOI: 10.3748/wjg.v12.i20.3253] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
442 Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, Sasaki T, Hyodo I, Yachi Y, Onuma H, Ohtsu A. Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Invest New Drugs 2014;32:473-80. [PMID: 24337768 DOI: 10.1007/s10637-013-0056-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
443 Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. J Gastrointest Oncol 2014;5:99-103. [PMID: 24772337 DOI: 10.3978/j.issn.2078-6891.2014.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
444 Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91. [PMID: 17537235 DOI: 10.1186/1471-2407-7-91] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
445 Kassahun WT. Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis. World J Surg Oncol 2015;13:61. [PMID: 25890279 DOI: 10.1186/s12957-014-0420-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
446 Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. Pharmacoeconomics 2009;27:597-608. [PMID: 19663530 DOI: 10.2165/11310110-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
447 Huang L, Zhang T, Xie C, Liao X, Yu Q, Feng J, Ma H, Dai J, Li M, Chen J. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One. 2013;8:e77223. [PMID: 24143213 DOI: 10.1371/journal.pone.0077223] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
448 Linton SS, Sherwood SG, Drews KC, Kester M. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016;8:208-22. [PMID: 26153136 DOI: 10.1002/wnan.1358] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
449 Joseph EK, Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J Pain 2009;10:534-41. [PMID: 19231296 DOI: 10.1016/j.jpain.2008.12.003] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
450 Lin YL, Liau JY, Yu SC, Ou DL, Lin LI, Tseng LH, Chang YL, Yeh KH, Cheng AL. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. PLoS One 2012;7:e50701. [PMID: 23209813 DOI: 10.1371/journal.pone.0050701] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
451 Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol 2014;45:1381-90. [PMID: 25175642 DOI: 10.3892/ijo.2014.2556] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
452 Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer. 2009;101:12-18. [PMID: 19491895 DOI: 10.1038/sj.bjc.6605114] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
453 Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol 2011;13:162-78. [PMID: 21421461 DOI: 10.1007/s12094-011-0636-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
454 Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer. 2014;14:897. [PMID: 25487708 DOI: 10.1186/1471-2407-14-897] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
455 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:106-115. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558] [Reference Citation Analysis]
456 Li J, Xiang Q, Wang M, Zhang H, Liang R. All-Trans Retinoic Acid Enhances Chemosensitivity to 5-FU by Targeting miR-378c/E2F7 Axis in Colorectal Cancer. J Oncol 2021;2021:5338934. [PMID: 34335757 DOI: 10.1155/2021/5338934] [Reference Citation Analysis]
457 Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol. 2010;69:58-66. [PMID: 20078613 DOI: 10.1111/j.1365-2125.2009.03556.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
458 Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8:230-242. [PMID: 27239240 DOI: 10.1177/1758834016635888] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
459 Qadan M, D'Angelica MI. Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease. Curr Colorectal Cancer Rep. 2015;11:369-377. [PMID: 28090195 DOI: 10.1007/s11888-015-0290-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
460 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. [Therapy response of liver tumors after selective internal radiation therapy]. Radiologe. 2008;48:839-849. [PMID: 18766324 DOI: 10.1007/s00117-008-1730-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
461 Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M. Antibody targeting of claudin-1 as a potential colorectal cancer therapy. J Exp Clin Cancer Res 2017;36:89. [PMID: 28659146 DOI: 10.1186/s13046-017-0558-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
462 Watkins DJ, Chau I, Cunningham D, Mudan SS, Karanjia N, Brown G, Ashley S, Norman AR, Gillbanks A. Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. Br J Cancer 2010;102:255-61. [PMID: 20087355 DOI: 10.1038/sj.bjc.6605508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
463 Tanaka K, Ichikawa Y, Endo I. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol. 2011;16:452-463. [PMID: 21786210 DOI: 10.1007/s10147-011-0291-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
464 't Lam-Boer J, Mol L, Verhoef C, de Haan AF, Yilmaz M, Punt CJ, de Wilt JH, Koopman M. The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer--a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer 2014;14:741. [PMID: 25277170 DOI: 10.1186/1471-2407-14-741] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
465 Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34. [PMID: 28349281 DOI: 10.1007/s10147-017-1101-6] [Cited by in Crossref: 400] [Cited by in F6Publishing: 276] [Article Influence: 100.0] [Reference Citation Analysis]
466 Subramani B, Ratnavelu K, Pullai CR, Krishnan K, Sugadan SD, Deng X, Hiroshi T. Autologous immune enhancement therapy: A case report of a stage IV colonic cancer. Oncol Lett 2013;5:1611-4. [PMID: 23761827 DOI: 10.3892/ol.2013.1246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
467 Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377:1749-1759. [PMID: 21570111 DOI: 10.1016/s0140-6736(11)60399-1] [Cited by in Crossref: 250] [Cited by in F6Publishing: 93] [Article Influence: 25.0] [Reference Citation Analysis]
468 Marshall JL. Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? J Oncol 2009;2009:937305. [PMID: 20016807 DOI: 10.1155/2009/937305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
469 Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer 2012;106:799-804. [PMID: 22315053 DOI: 10.1038/bjc.2012.17] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
470 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Hashiguchi T, Nakatani A, Marusasa T, Muraki A, Nagaoka I, Futagawa S. Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test. Exp Ther Med 2010;1:325-9. [PMID: 22993545 DOI: 10.3892/etm_00000050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
471 Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. A phase I study of an oral simulated FOLFOX with high dose capecitabine. Invest New Drugs 2009;27:461-8. [PMID: 19129971 DOI: 10.1007/s10637-008-9210-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
472 Audisio RA, Papamichael D. Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol. 2012;9:716-725. [PMID: 23045000 DOI: 10.1038/nrgastro.2012.196] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
473 Catenacci DV, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin Oncol 2011;38:284-308. [PMID: 21421118 DOI: 10.1053/j.seminoncol.2011.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
474 Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J, Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 2008;99:1607-12. [PMID: 18941461 DOI: 10.1038/sj.bjc.6604691] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
475 Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study). Jpn J Clin Oncol. 2012;42:134-138. [PMID: 22167662 DOI: 10.1093/jjco/hyr180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
476 Holch J, Stintzing S, Heinemann V. Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. Visc Med 2016;32:178-83. [PMID: 27493945 DOI: 10.1159/000446052] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 4.4] [Reference Citation Analysis]
477 Guthrie L, Gupta S, Daily J, Kelly L. Human microbiome signatures of differential colorectal cancer drug metabolism. NPJ Biofilms Microbiomes. 2017;3:27. [PMID: 29104759 DOI: 10.1038/s41522-017-0034-1] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 14.3] [Reference Citation Analysis]
478 Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, O'Connell MJ, Sargent DJ. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. J Clin Oncol. 2013;31:3656-3663. [PMID: 23980089 DOI: 10.1200/jco.2013.49.4344] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
479 Hakami R, Alali MN, Alshammari T, AlShammari S, Alyahya Z, Ayesh M, AlSaad K, Abduljabbar A. A cutaneous metastasis of unresectable rectal adenocarcinoma: A case report and literature review. Int J Surg Case Rep 2020;71:95-101. [PMID: 32446230 DOI: 10.1016/j.ijscr.2020.04.102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
480 Albuquerque C, Pebre Pereira L. Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment? Adv Exp Med Biol 2018;1110:75-100. [PMID: 30623367 DOI: 10.1007/978-3-030-02771-1_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
481 Boland PM, Fakih M. The emerging role of neoadjuvant chemotherapy for rectal cancer. J Gastrointest Oncol. 2014;5:362-373. [PMID: 25276409 DOI: 10.3978/j.issn.2078-6891.2014.060] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
482 Kreidieh M, Mukherji D, Temraz S, Shamseddine A. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. Biomed Res Int 2020;2020:9037217. [PMID: 32090113 DOI: 10.1155/2020/9037217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
483 Khatkov IE, Kagramanova AV, Zakharzhevskaya NB, Babikova EA, Generozov EV, Shcherbakov PL, Parfenov AI. [Current principles in the screening, diagnosis, and therapy of colorectal cancer]. Ter Arkh 2016;88:90-6. [PMID: 27135106 DOI: 10.17116/terarkh201688290-96] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
484 Freeman K, Saunders MP, Uthman OA, Taylor-Phillips S, Connock M, Court R, Gurung T, Sutcliffe P, Clarke A. Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review. BMC Cancer 2016;16:523. [PMID: 27456697 DOI: 10.1186/s12885-016-2581-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
485 Gherman A, Balacescu L, Gheorghe-Cetean S, Vlad C, Balacescu O, Irimie A, Lisencu C. Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers. Int J Mol Sci 2020;21:E2089. [PMID: 32197436 DOI: 10.3390/ijms21062089] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
486 Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573. [PMID: 19998273 DOI: 10.1002/cncr.24760]] [Reference Citation Analysis]
487 Suenaga M, Nishina T, Mizunuma N, Yasui H, Ura T, Denda T, Ikeda J, Esaki T, Nishisaki H, Takano Y, Sugiyama Y, Muro K. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). BMC Cancer 2015;15:176. [PMID: 25884814 DOI: 10.1186/s12885-015-1175-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
488 Şahin U, Demirer T. Graft-versus-cancereffect and innovative approaches in thetreatment of refractory solid tumors. Turk J Med Sci 2020;50:1697-706. [PMID: 32178508 DOI: 10.3906/sag-1911-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
489 Stintzing S. Management of colorectal cancer. F1000Prime Rep 2014;6:108. [PMID: 25580262 DOI: 10.12703/P6-108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
490 Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer. 2013;13:67. [PMID: 23391248 DOI: 10.1186/1471-2407-13-67] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
491 Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75-89. [PMID: 22423266 DOI: 10.1177/1758834011431592] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
492 Jeon EK, Hong SH, Kim TH, Jung SE, Park JC, Won HS, Ko YH, Rho SY, Hong YS. Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. Cancer Res Treat 2011;43:148-53. [PMID: 22022291 DOI: 10.4143/crt.2011.43.3.148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
493 Was H, Czarnecka J, Kominek A, Barszcz K, Bernas T, Piwocka K, Kaminska B. Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. Cancer Biol Ther 2018;19:63-75. [PMID: 29053388 DOI: 10.1080/15384047.2017.1385675] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
494 Feliu J, Salud A, Escudero P, Lopez-Gómez L, Bolaños M, Galán A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, González-Barón M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969-75. [PMID: 16552438 DOI: 10.1038/sj.bjc.6603047] [Cited by in Crossref: 82] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
495 Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G, Shiomi A, Kagimura T, Sugihara K. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. Int J Clin Oncol 2019;24:516-25. [PMID: 30612267 DOI: 10.1007/s10147-018-01393-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
496 Shibata Y, Baba E, Ariyama H, Arita S, Isobe T, Kusaba H, Mitsugi K, Nakano S, Akashi K. Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. Oncol Lett 2010;1:423-6. [PMID: 22966319 DOI: 10.3892/ol_00000074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
497 Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7:309-317. [PMID: 20368727 DOI: 10.1038/nrclinonc.2010.43] [Cited by in Crossref: 212] [Cited by in F6Publishing: 157] [Article Influence: 19.3] [Reference Citation Analysis]
498 Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M; Aide et Recherche en Cancerologie Digestive Group. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Netw Open 2019;2:e1911750. [PMID: 31539075 DOI: 10.1001/jamanetworkopen.2019.11750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
499 Kang DH, Woo J, Kim H, Kim SY, Ji S, Jaygal G, Ahn TS, Kim HJ, Kwak HJ, Kim CJ, Baek MJ, Jeong D. Prognostic Relevance of HJURP Expression in Patients with Surgically Resected Colorectal Cancer. Int J Mol Sci 2020;21:E7928. [PMID: 33114545 DOI: 10.3390/ijms21217928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
500 Bonadio RC, Amor Divino PH, Obando JSM, Lima KCA, Recchimuzzi DZ, Kruger JAP, Saragiotto DF, Capareli FC, Hoff PM. Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. J Glob Oncol. 2019;5:1-6. [PMID: 31479339 DOI: 10.1200/jgo.19.00180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist. 2012;17:201-211. [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
502 Sabet A, Meyer C, Aouf A, Sabet A, Ghamari S, Pieper CC, Mayer K, Biersack HJ, Ezziddin S. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging 2015;42:370-6. [PMID: 25351506 DOI: 10.1007/s00259-014-2935-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
503 Jones RP, Dunne D, Sutton P, Malik HZ, Fenwick SW, Terlizzo M, O'Grady E, Koelblinger C, Stättner S, Stremitzer S, Gruenberger T, Poston GJ. Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series. HPB (Oxford) 2013;15:71-7. [PMID: 23216781 DOI: 10.1111/j.1477-2574.2012.00587.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
504 Kobayashi A, Miyagawa S. Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol. 2010;2:380-389. [PMID: 21160889 DOI: 10.4251/wjgo.v2.i10.380] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
505 Hazama S, Nakamura Y, Tanaka H, Hirakawa K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, Furuya T, Nishimura T, Sakata K, Yoshimatsu K, Takenouchi H, Tsunedomi R, Inoue Y, Kanekiyo S, Shindo Y, Suzuki N, Yoshino S, Shinozaki H, Kamiya A, Furukawa H, Yamanaka T, Fujita T, Kawakami Y, Oka M. A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med 2014;12:108. [PMID: 24884643 DOI: 10.1186/1479-5876-12-108] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
506 Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P, Chilcott J. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 2006;95:1195-201. [PMID: 17031407 DOI: 10.1038/sj.bjc.6603348] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
507 Chauhan N, Mulcahy MF, Salem R, Benson Iii AB, Boucher E, Bukovcan J, Cosgrove D, Laframboise C, Lewandowski RJ, Master F, El-Rayes B, Strosberg JR, Sze DY, Sharma RA. TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.JMIR Res Protoc. 2019;8:e11545. [PMID: 30664496 DOI: 10.2196/11545] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
508 Shiomi K, Naito M, Sato T, Nakamura T, Nakashima H, Naito M, Mikubo M, Matsui Y, Watanabe M, Satoh Y. Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer. Ann Med Surg (Lond) 2017;20:19-25. [PMID: 28702182 DOI: 10.1016/j.amsu.2017.06.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
509 Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2011;10:210-6. [PMID: 21855046 DOI: 10.1016/j.clcc.2011.03.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
510 Uchida K, Hayashi K, Kuramochi H, Nakajima G, Inoue Y, Yamamoto M. Combination therapy of S-1 and CDDP for patients with colorectal cancer. J Cancer Res Clin Oncol 2007;133:841-6. [PMID: 17479286 DOI: 10.1007/s00432-007-0226-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
511 Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:143-50. [PMID: 22285706 DOI: 10.1016/j.clcc.2011.12.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 6.9] [Reference Citation Analysis]
512 Vijayasekar C, Noormohamed S, Cheetham MJ. Late recurrence of large peri-stomal metastasis following abdomino-perineal resection of rectal cancer. World J Surg Oncol 2008;6:96. [PMID: 18771600 DOI: 10.1186/1477-7819-6-96] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
513 Tonini G, Calvieri A, Vincenzi B, Santini D. First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. Onco Targets Ther 2009;2:73-82. [PMID: 20616896 DOI: 10.2147/ott.s3465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
514 Hachiya H, Ishizuka M, Takagi K, Iwasaki Y, Shibuya N, Nishi Y, Aoki T, Kubota K. Clinical significance of the globulin-to-albumin ratio for prediction of postoperative survival in patients with colorectal cancer. Ann Gastroenterol Surg 2018;2:434-41. [PMID: 30460347 DOI: 10.1002/ags3.12201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
515 Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, Rogowski W, Huang X, Wu B, Warner D, Jain R, Tebbutt NC. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013;108:503-11. [PMID: 23361051 DOI: 10.1038/bjc.2012.594] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
516 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
517 Ahmed S, Johnson K, Ahmed O, Iqbal N. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis 2014;29:1031-42. [PMID: 24953060 DOI: 10.1007/s00384-014-1928-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
518 Yaghobi Joybari A, Behzadi B, Azadeh P, Alahyari S. The Outcome of Induction Chemotherapy, Followed by Neoadjuvant Chemoradiotherapy and Surgery, in Locally Advanced Rectal Cancer. Iran J Pathol 2021;16:266-73. [PMID: 34306122 DOI: 10.30699/IJP.2021.130482.2441] [Reference Citation Analysis]
519 Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. Transl Oncol 2019;12:550-60. [PMID: 30639964 DOI: 10.1016/j.tranon.2018.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
520 Papadimitriou K, Rolfo C, Dewaele E, Van De Wiel M, Van den Brande J, Altintas S, Huizing M, Specenier P, Peeters M. Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer. Curr Treat Options Oncol 2015;16:18. [PMID: 25813037 DOI: 10.1007/s11864-015-0333-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
521 Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:866-71. [PMID: 20038727 DOI: 10.1200/JCO.2009.23.6125] [Cited by in Crossref: 112] [Cited by in F6Publishing: 47] [Article Influence: 9.3] [Reference Citation Analysis]
522 Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, Song FY, Wang FF, Zhu XH, Liao WJ, Liao WT, Ding YQ, Liang L. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18:91. [PMID: 31064356 DOI: 10.1186/s12943-019-1019-x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 114] [Article Influence: 56.5] [Reference Citation Analysis]
523 Braun MS, Seymour MT. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol. 2011;3:43-52. [PMID: 21789155 DOI: 10.1177/1758834010388342] [Cited by in Crossref: 59] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
524 Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019;10:75-85. [PMID: 30815374 DOI: 10.5306/wjco.v10.i2.75] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
525 Cui CH, Huang SX, Qi J, Zhu HJ, Huang ZH, Yu JL. Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis. Oncotarget 2015;6:44005-18. [PMID: 26515604 DOI: 10.18632/oncotarget.5875] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
526 Rusthoven CG, Schefter TE. Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases. Hepat Oncol 2014;1:81-94. [PMID: 30190943 DOI: 10.2217/hep.13.12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
527 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, Ochi T, Okubo S, Futagawa S, Mashiko S, Nagaoka I. Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2012;4:621-4. [PMID: 23205073 DOI: 10.3892/ol.2012.823] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
528 Kurniali PC, Hrinczenko B, Al-Janadi A. Management of locally advanced and metastatic colon cancer in elderly patients. World J Gastroenterol. 2014;20:1910-1922. [PMID: 24616568 DOI: 10.3748/wjg.v20.i8.1910] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
529 Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectr 2020;4:pkz078. [PMID: 32259016 DOI: 10.1093/jncics/pkz078] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
530 Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138:65-72. [PMID: 21960318 DOI: 10.1007/s00432-011-1061-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
531 Shimizu S, Iida S, Ishiguro M, Uetake H, Ishikawa T, Takagi Y, Kobayashi H, Higuchi T, Enomoto M, Mogushi K, Mizushima H, Tanaka H, Sugihara K. Methylated BNIP3 gene in colorectal cancer prognosis. Oncol Lett 2010;1:865-72. [PMID: 22966396 DOI: 10.3892/ol_00000153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
532 Chen D, Gu K, Wang H. Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies. Cancer Manag Res 2019;11:1705-16. [PMID: 30863179 DOI: 10.2147/CMAR.S196170] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
533 Valentí Moreno V, Brunet Vidal J, Manzano Alemany H, Salud Salvia A, Llobera Serentill M, Cabezas Montero I, Servitja Tormo S, Sopena Bert E, Gumà Padró J. Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients. Clin Transl Oncol 2006;8:208-12. [PMID: 16648121 DOI: 10.1007/s12094-006-0012-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
534 Hur H, Kim NK, Kim HG, Min BS, Lee KY, Shin SJ, Cheon JH, Choi SH. Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. Br J Cancer. 2012;106:53-60. [PMID: 22068817 DOI: 10.1038/bjc.2011.469] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
535 Deng T, Zhang L, Liu XJ, Xu JM, Bai YX, Wang Y, Han Y, Li YH, Ba Y. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study. Med Oncol. 2013;30:752. [PMID: 24174316 DOI: 10.1007/s12032-013-0752-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
536 Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). Int J Clin Oncol 2019;24:1223-30. [PMID: 31144145 DOI: 10.1007/s10147-019-01473-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
537 Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer 2017;123:4506-14. [PMID: 28708932 DOI: 10.1002/cncr.30880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
538 Nakayama G, Uehara K, Ishigure K, Yokoyama H, Ishiyama A, Eguchi T, Tsuboi K, Ohashi N, Fujii T, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemother Pharmacol 2012;70:575-81. [PMID: 22886005 DOI: 10.1007/s00280-012-1948-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
539 Lin YM, Chen CI, Hsiang YP, Hsu YC, Cheng KC, Chien PH, Pan HL, Lu CC, Chen YJ. Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. Int J Mol Sci 2018;19:E1763. [PMID: 29899208 DOI: 10.3390/ijms19061763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
540 De Mattia E, Polesel J, Roncato R, Labriet A, Bignucolo A, Gagno S, Buonadonna A, D'Andrea M, Lévesque E, Jonker D, Couture F, Guillemette C, Cecchin E, Toffoli G. IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. Cancers (Basel) 2021;13:1705. [PMID: 33916844 DOI: 10.3390/cancers13071705] [Reference Citation Analysis]
541 Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619-2626. [PMID: 22431703 DOI: 10.1093/annonc/mds053] [Cited by in Crossref: 241] [Cited by in F6Publishing: 175] [Article Influence: 26.8] [Reference Citation Analysis]
542 Field KM, Kosmider S, Jefford M, Jennens R, Green M, Gibbs P. Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice? J Oncol Pract 2008;4:271-6. [PMID: 20856756 DOI: 10.1200/JOP.0852002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
543 Yamada Y, Muro K, Takahashi K, Baba H, Komatsu Y, Satoh T, Goto M, Mishima H, Watanabe M, Sakata Y, Morita S, Shimada Y, Takenaka N, Hirooka T, Sugihara K. Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. Glob Health Med 2020;2:240-6. [PMID: 33330814 DOI: 10.35772/ghm.2020.01050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
544 Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007;96:206-12. [PMID: 17242694 DOI: 10.1038/sj.bjc.6603561] [Cited by in Crossref: 62] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
545 Rosenthal DI, Catalano PJ, Haller DG, Landry JC, Sigurdson ER, Spitz FR, Benson AB. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. Int J Radiat Oncol Biol Phys. 2008;72:108-113. [PMID: 18722265 DOI: 10.1016/j.ijrobp.2008.05.054] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
546 Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Ther Adv Med Oncol 2015;7:153-69. [PMID: 26673925 DOI: 10.1177/1758834015572343] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
547 Nozawa H, Takiyama H, Hasegawa K, Kawai K, Hata K, Tanaka T, Nishikawa T, Sasaki K, Kaneko M, Murono K, Emoto S, Sonoda H, Nakajima J. Adjuvant chemotherapy improves prognosis of resectable stage IV colorectal cancer: a comparative study using inverse probability of treatment weighting. Ther Adv Med Oncol 2019;11:1758835919838960. [PMID: 31019569 DOI: 10.1177/1758835919838960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
548 Zhang S, Shi L, Mao D, Peng W, Sheng C, Ding C, Lin F, Lei C, Zhang S. Use of Jianpi Jiedu Herbs in Patients with Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2018;2018:6180810. [PMID: 29619070 DOI: 10.1155/2018/6180810] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
549 Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101:1658-1663. [PMID: 19826418 DOI: 10.1038/sj.bjc.6605374] [Cited by in Crossref: 105] [Cited by in F6Publishing: 93] [Article Influence: 8.8] [Reference Citation Analysis]
550 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
551 Hayashi T, Shimokawa M, Matsuo K, Nishimura J, Iihara H, Nakano T, Egawa T. 5HT3 RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer. Cancer Sci 2021;112:744-50. [PMID: 33274555 DOI: 10.1111/cas.14757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
552 Hewes JC, Dighe S, Morris RW, Hutchins RR, Bhattacharya S, Davidson BR. Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg. 2007;31:353-64; discussion 365. [PMID: 17219289 DOI: 10.1007/s00268-006-0103-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
553 Komatsu Y, Ishioka C, Shimada K, Yamada Y, Gamoh M, Sato A, Yamaguchi T, Yuki S, Morita S, Takahashi S, Goto R, Kurihara M. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. BMC Cancer 2015;15:626. [PMID: 26353772 DOI: 10.1186/s12885-015-1630-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
554 Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009;:CD007045. [PMID: 19821394 DOI: 10.1002/14651858.CD007045.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
555 Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, Nagase M, Komatsu Y, Kato T, Miyata Y. First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study. Cancer Sci. 2012;103:1502-1507. [PMID: 22537162 DOI: 10.1111/j.1349-7006.2012.02320.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
556 Baba H, Watanabe M, Okabe H, Miyamoto Y, Sakamoto Y, Baba Y, Iwatsuki M, Chikamoto A, Beppu T. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. Br J Cancer 2012;107:1950-5. [PMID: 23169295 DOI: 10.1038/bjc.2012.502] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
557 Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome. J Gastrointest Surg 2007;11:860-8. [DOI: 10.1007/s11605-007-0149-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 133] [Article Influence: 12.8] [Reference Citation Analysis]
558 Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013;24:1560-1567. [PMID: 23493136 DOI: 10.1093/annonc/mdt056] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
559 Brandi G, Corbelli J, de Rosa F, Di Girolamo S, Longobardi C, Agostini V, Garajová I, La Rovere S, Ercolani G, Grazi GL. Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. Langenbecks Arch Surg. 2012;397:1069-1077. [PMID: 22711237 DOI: 10.1007/s00423-012-0974-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
560 Okamoto K, Nozawa H, Hongo K, Iida Y, Kawai K, Sasaki K, Murono K, Kita Y, Ishihara Y, Takabayashi N, Kobayashi R, Hiramatsu T, Ishihara S. Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study. Int J Clin Oncol 2021;26:1477-84. [PMID: 33991268 DOI: 10.1007/s10147-021-01932-w] [Reference Citation Analysis]
561 Nishigori H, Ito M, Nishizawa Y, Kohyama A, Koda T, Nakajima K, Nishizawa Y, Kobayashi A, Sugito M, Saito N. Laparoscopic surgery for palliative resection of the primary tumor in incurable stage IV colorectal cancer. Surg Endosc. 2012;26:3201-3206. [PMID: 22648097 DOI: 10.1007/s00464-012-2323-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
562 Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013;13:611. [PMID: 24373251 DOI: 10.1186/1471-2407-13-611] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
563 Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget 2016;7:34811-23. [PMID: 27166185 DOI: 10.18632/oncotarget.9187] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
564 Nishigori N, Matsumoto M, Koyama F, Hayakawa M, Hatakeyayama K, Ko S, Fujimura Y, Nakajima Y. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy. PLoS One. 2015;10:e0143136. [PMID: 26580395 DOI: 10.1371/journal.pone.0143136] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
565 Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut 2005;54:1194-202. [PMID: 16009693 DOI: 10.1136/gut.2004.062745] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
566 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
567 Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D’Argento E, Quirino M, Astone A, Cassano A. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer. 2007;10:104-111. [PMID: 17577620 DOI: 10.1007/s10120-007-0415-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
568 Wang H, Zhang L, Yang X, Jin Y, Pei S, Zhang D, Zhang H, Zhou B, Zhang Y, Lin D. PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer. Oncotarget 2015;6:14385-98. [PMID: 25965911 DOI: 10.18632/oncotarget.3775] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
569 Palshof JA, Høgdall EV, Poulsen TS, Linnemann D, Jensen BV, Pfeiffer P, Tarpgaard LS, Brünner N, Stenvang J, Yilmaz M, Nielsen DL. Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer 2017;17:48. [PMID: 28077117 DOI: 10.1186/s12885-016-3001-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
570 Puthiamadathil JM, Weinberg BA. Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil. Cancer Manag Res 2017;9:461-9. [PMID: 29056855 DOI: 10.2147/CMAR.S113320] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
571 Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs 2007;67:1851-67. [PMID: 17722954 DOI: 10.2165/00003495-200767130-00004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
572 Miyata Y, Touyama T, Kusumi T, Morita Y, Mizunuma N, Taniguchi F, Manabe M. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. Int J Clin Oncol. 2016;21:696-703. [PMID: 26710796 DOI: 10.1007/s10147-015-0937-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
573 Petrelli F, Barni S; Anti-EGFR agents for liver metastases. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis. 2012;27:997-1004. [PMID: 22358385 DOI: 10.1007/s00384-012-1438-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
574 Huh JW, Park YA, Lee KY, Sohn SK. Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication. Yonsei Med J. 2009;50:697-703. [PMID: 19881975 DOI: 10.3349/ymj.2009.50.5.697] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
575 Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne CH, Seymour MT, de Gramont A, Goldberg RM, Sargent DJ. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol 2011;29:2781-6. [PMID: 21646604 DOI: 10.1200/JCO.2010.33.5281] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
576 Scevola G, Loreni G, Rastelli M, Sposato S, Ramponi S, Miele V. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Med Oncol 2017;34:37. [PMID: 28160267 DOI: 10.1007/s12032-017-0890-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
577 Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res 2009;18:1095-103. [PMID: 19626462 DOI: 10.1007/s11136-009-9513-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
578 Xu J, Qin X, Wang J, Zhang S, Zhong Y, Ren L, Wei Y, Zeng S, Wan D, Zheng S; Society of Surgery; Chinese Medical Association; Committee of Colorectal Cancer, Chinese Anti-cancer Association. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol. 2011;137:1379-1396. [PMID: 21796415 DOI: 10.1007/s00432-011-0999-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
579 Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D 2011;11:101-11. [PMID: 21679003 DOI: 10.2165/11590440-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
580 Oppelt P, Betbadal A, Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med 2015;20:153-61. [PMID: 25832603 DOI: 10.1177/1358863X14568705] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 5.4] [Reference Citation Analysis]
581 Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kimura K, Amano R, Hirakawa K, Ohira M. The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study. BMC Cancer 2019;19:241. [PMID: 30885163 DOI: 10.1186/s12885-019-5468-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
582 Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M, Chopitea A, Bandres E, Garcia-Foncillas J. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer 2010;103:1529-35. [PMID: 20940716 DOI: 10.1038/sj.bjc.6605908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
583 Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci 2015;106:1722-9. [PMID: 26426205 DOI: 10.1111/cas.12827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
584 Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2013;17:533-46, vii. [PMID: 24099016 DOI: 10.1016/j.cld.2013.07.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
585 Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain. 2010;6:15. [PMID: 20205720 DOI: 10.1186/1744-8069-6-15] [Cited by in Crossref: 107] [Cited by in F6Publishing: 108] [Article Influence: 9.7] [Reference Citation Analysis]
586 Aung KL, Stockley TL, Serra S, Kamel-Reid S, Bedard PL, Siu LL. Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Cold Spring Harb Mol Case Stud 2016;2:a001016. [PMID: 27626067 DOI: 10.1101/mcs.a001016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
587 Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17:1486-95. [PMID: 23015662 DOI: 10.1634/theoncologist.2012-0190] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 7.2] [Reference Citation Analysis]
588 Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol. 2015;7:47-54. [PMID: 26090075 DOI: 10.4251/wjgo.v7.i6.47] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
589 Kim JS, Kim YG, Park EJ, Kim B, Lee HK, Hong JT, Kim Y, Han SB. Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells. Immune Netw 2016;16:99-108. [PMID: 27162526 DOI: 10.4110/in.2016.16.2.99] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
590 Kim JY, Kim JS, Baek MJ, Kim CN, Choi WJ, Park DK, Namgung H, Lee SC, Lee SJ. Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases. J Korean Surg Soc 2013;85:154-60. [PMID: 24106681 DOI: 10.4174/jkss.2013.85.4.154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
591 Bajetta E, Di Bartolomeo M, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Lo Vullo S, Aitini E, Isa L, Barone C. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer. 2007;96:439-444. [PMID: 17245343 DOI: 10.1038/sj.bjc.6603493] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
592 Inoue Y, Fujii K, Tashiro K, Ishii M, Masubuchi S, Yamamoto M, Shimizu T, Asakuma M, Hirokawa F, Hayashi M, Narumi Y, Uchiyama K. Preoperative Chemotherapy May Not Influence the Remnant Liver Regenerations and Outcomes After Hepatectomy for Colorectal Liver Metastasis. World J Surg. 2018;42:3316-3330. [PMID: 29549511 DOI: 10.1007/s00268-018-4590-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
593 Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol 2009;1:55-68. [PMID: 21789113 DOI: 10.1177/1758834009343302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
594 Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-8. [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259] [Cited by in Crossref: 128] [Cited by in F6Publishing: 100] [Article Influence: 10.7] [Reference Citation Analysis]
595 Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, Brenner B, Flowers CR, Hall PS. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. Oncologist 2017;22:694-9. [PMID: 28592621 DOI: 10.1634/theoncologist.2016-0455] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
596 Torres OJ, Marques MC, Santos FN, Farias IC, Coutinho AK, Oliveira CV, Kalil AN, Mello CA, Kruger JA, Fernandes GD, Quireze C Jr, Murad AM, Silva MJ, Zurstrassen CE, Freitas HC, Cruz MR, Weschenfelder R, Linhares MM, Castro LD, Vollmer C, Dixon E, Ribeiro HS, Coimbra FJ. BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arq Bras Cir Dig 2016;29:173-9. [PMID: 27759781 DOI: 10.1590/0102-6720201600030011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
597 Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011;15:410-415. [PMID: 21253876 DOI: 10.1007/s11605-011-1423-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
598 Shamimi-Noori S, Gonsalves CF, Shaw CM. Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.Semin Intervent Radiol. 2017;34:145-166. [PMID: 28579683 DOI: 10.1055/s-0037-1602712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
599 Lee KW, Kim BJ, Kim MJ, Han HS, Kim JW, Park YI, Park SR. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. Cancer Res Treat. 2017;49:706-716. [PMID: 27764906 DOI: 10.4143/crt.2016.216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
600 Bayoglu İV, Yildiz I, Varol U, Cokmert S, Alacacıoğlu A, Kucukzeybek Y, Akyol M, Demir L, Dirican A, Tarhan O. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemp Oncol (Pozn) 2015;19:385-90. [PMID: 26793023 DOI: 10.5114/wo.2015.53374] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
601 Ferrari LF, Chum A, Bogen O, Reichling DB, Levine JD. Role of Drp1, a key mitochondrial fission protein, in neuropathic pain. J Neurosci 2011;31:11404-10. [PMID: 21813700 DOI: 10.1523/JNEUROSCI.2223-11.2011] [Cited by in Crossref: 60] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
602 Dattatreya S. Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer 2013;2:179-85. [PMID: 24455615 DOI: 10.4103/2278-330X.114152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
603 Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704-1719. [PMID: 19436303 DOI: 10.1038/sj.bjc.6605061] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
604 Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? Br J Cancer 2006;94:363-71. [PMID: 16465172 DOI: 10.1038/sj.bjc.6602960] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
605 Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. World J Gastroenterol 2014;20:7602-21. [PMID: 24976699 DOI: 10.3748/wjg.v20.i24.7602] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
606 Fang YJ, Wu XJ, Zhao Q, Li LR, Lu ZH, Ding PR, Zhang RX, Kong LH, Wang FL, Lin JZ, Chen G, Pan ZZ, Wan DS. Hospital-based colorectal cancer survival trend of different tumor locations from 1960s to 2000s. PLoS One 2013;8:e73528. [PMID: 24069202 DOI: 10.1371/journal.pone.0073528] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
607 Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9:157-161. [PMID: 20643620 DOI: 10.3816/ccc.2010.n.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
608 Kurkjian C, Kummar S. Advances in the treatment of metastatic colorectal cancer. Am J Ther 2009;16:412-20. [PMID: 19955859 DOI: 10.1097/MJT.0b013e3181907ed9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
609 Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer Chemother Pharmacol 2021;88:543-53. [PMID: 34117512 DOI: 10.1007/s00280-021-04314-1] [Reference Citation Analysis]
610 Qingwei Z, Dongsheng H, Duo L, Youlei W, Songxia Y, Ziqi Y, Lanjuan L. Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients. Front Oncol 2020;10:1542. [PMID: 32984012 DOI: 10.3389/fonc.2020.01542] [Reference Citation Analysis]
611 Zhao J, Shi L, Ji M, Wu J, Wu C. The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer. Mol Clin Oncol 2017;6:856-60. [PMID: 28588777 DOI: 10.3892/mco.2017.1247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
612 Iwata Y, Matsuhashi N, Takahashi T, Suetsugu T, Fukada M, Yasufuku I, Imai T, Tanahashi T, Mori R, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Futamura M, Miyazaki T, Yoshida K. Ascending colon cancer with synchronous right external iliac lymph node metastasis. Int Cancer Conf J 2020;9:162-7. [PMID: 32582524 DOI: 10.1007/s13691-020-00419-1] [Reference Citation Analysis]
613 Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol 2013;30:604. [PMID: 23686699 DOI: 10.1007/s12032-013-0604-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
614 Marschner N, Arnold D, Engel E, Hutzschenreuter U, Rauh J, Freier W, Hartmann H, Frank M, Jänicke M. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study. Clin Epidemiol 2015;7:295-303. [PMID: 25945067 DOI: 10.2147/CLEP.S73857] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
615 Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep 2009;11:200-8. [PMID: 19336012 DOI: 10.1007/s11912-009-0029-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
616 Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean J Intern Med 2019;34:165-77. [PMID: 29172407 DOI: 10.3904/kjim.2016.348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
617 Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S3-17. [PMID: 20680105 DOI: 10.3747/co.v17is1.616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
618 Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, Baiget M. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer. 2011;105:53-57. [PMID: 21654688 DOI: 10.1038/bjc.2011.206] [Cited by in Crossref: 74] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
619 Popescu I, Alexandrescu ST. Surgical options for initially unresectable colorectal liver metastases. HPB Surg 2012;2012:454026. [PMID: 23082042 DOI: 10.1155/2012/454026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
620 Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemother Pharmacol 2017;80:599-608. [PMID: 28744667 DOI: 10.1007/s00280-017-3380-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
621 Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer 2009;115:2081-91. [PMID: 19309745 DOI: 10.1002/cncr.24246] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]